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ABSTRACT OF DISSERTATION 
 
   
NANOMETER-SCALE MEMBRANE ELECTRODE SYSTEMS FOR ACTIVE 
PROTEIN SEPARATION, ENZYME IMMOBILIZATION AND CELLULAR 
ELECTROPORATION 
Automated and continuous processes are the future trends in downstream protein 
purification. A functionalized nanometer-scale membrane electrode system, mimicking 
the function of cell wall transporters, can selectively capture genetically modified 
proteins and subsequently pump them through the system under programmed voltage 
pulses. Numerical study of the two-step pulse pumping cycles coupled with experimental 
His-GFP releasing study reveals the optimal 14s/1s pumping/repel pulse pumping 
condition at 10 mM bulk imidazole concentration in the permeate side. A separation 
factor for GFP: BSA of 9.7 was achieved with observed GFP electrophoretic mobility of 
3.1×10
-6 
cm
2 
s
-1
 V
-1 
at 10 mM bulk imidazole concentration and 14 s/1 s pumping/repel 
duration. The purification of His6-OleD Loki variant directly from crude E. coli extracts 
expression broth was demonstrated using the pulse pumping process, simplifying the 
separation process as well as reducing biopharmaceutical production costs. The 
enzymatic reactions showed that His6-OleD Loki was still active after purification. 
A nanoporous membrane/electrode system with directed flow carrying reagents to 
sequentially attached enzymes to mimic nature’s enzymes-complex system was 
demonstrated. The substrates residence time on the immobilized enzyme can be precisely 
controlled by changing the pumping rate and thereby prevent a secondary hydrolysis 
reaction. Immobilized enzyme showed long term storage longevity with activity half-life 
of 50 days at 4℃ and the ability to be regenerated.  One-step immobilization and 
purification of His-tagged OleD Loki variant directly from expression broth, yielded 98% 
Uridine Diphosphate glycosylation and 80% 4-methylumbelliferone glycosylation 
conversion efficiency for the sequential reaction. 
A flow-through electroporation system, based on a novel membrane/electrode design, for 
the delivery of membrane-impermeant molecules into Model Leukocyte cells was 
demonstrated. The ability to apply low voltage between two short distance electrodes 
contributes to high cell viability. The flow-through system can be easily scaled-up by 
varying the micro-fluidic channel geometry and/or the applied voltage pulse frequency. 
More importantly, the system allows the electrophoretical pumping of molecules from the 
reservoir across the membrane/electrode system to the micro-fluidic channel for 
transfection, which reduces large amount of reagents used. 
 
KEYWORDS: Nanoporous electrode, Dynamic membrane, Protein separation, Enzyme 
immobilization, Cell electroporation 
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Chapter 1 : Introduction 
1.1 Synthetic Membranes  
 
     Synthetic membranes have found wide-ranging applications in water desalination, gas 
separations, drug delivery, and hemodialysis since the middle of last century [1]. The 
history of membrane industry is very short; however, the market is large and is growing 
more than 10% per year. The membrane market is about 15 billion in 2012 and is 
estimated to double by 2020. Basically, there are three major commercially available 
synthetic membranes types according to the production process; polymeric membranes, 
“track-etch” membranes and ceramic membranes. Polymeric membranes are the most 
widely used membrane in industry due to their high performance and low relative cost. 
Many different polymers such as cellulose acetate, polyvinylchloride (PVC), 
polytetrafluoroethylene (PTFE), polyvinylidene fluoride (PVDF), polyethylene (PE) have 
been used for polymeric membranes synthesis. These polymer-based membranes surfaces 
are often modified with different chemistry to further increase performance and used for 
various applications [2].  
    Water desalination is the major application of polymeric membranes in industry. Water 
is one of the most precious resources in the world. However, countries like Singapore 
have little access to water. Desalination of seawater is a good choice for such countries. 
Traditional desalination method is vacuum distillation. Many vacuum distillation plants 
have been built around the world though it is a relatively expensive desalination method. 
Desalination using membrane technology is an alternative approach, and in fact it’s a 
more economical method [3]. Reverse osmosis membranes have been extensively used 
2 
 
for desalination [4]. Reverse osmosis (RO) works by applying a pressure to overcome 
osmotic pressure and push water pass through the semipermeable membrane. Only water 
can pass through the RO membrane, all other molecule and ions can’t pass through the 
RO membrane. Polysulfone open support membranes coated with aromatic polyamides 
using an interfacial polymerization reaction to form a thin skin with ‘free volume’ that 
supports selective water transport. The next most significant application of polymeric 
membranes is in gas separation area where gasses are also selectively transported through 
‘free’ volume of the polymer skin layer. The global warming calls for the capture of CO2 
in coal plant. Membrane technologies have been extensively studied for the capture of 
CO2 from coal-fired power-plant flue gas [5].  Also, polymeric membranes have been 
used for food and pharmaceutical industry to remove impurities from products.  
    One disadvantage of polymeric membranes is their randomly distributed pore size, 
limiting their application in precise size-based filtration. “Track-etch” membranes, such 
as Polycarbonate track-etch (PCTE), are made from thin film material via track-etch 
method. A two-step method combining charged particle bombardment and chemical 
etching is used to create discrete pores in the “Track-etch” membranes. The pore sizes of 
“Track-etch” membranes are well-defined; however, the porosities are very low, limiting 
their applications in large-scale filtration. Ceramic membranes are made from inorganic 
materials (such as alumina oxides) can often tolerate extreme solvent conditions (extreme 
PH and temperature). Specifically, porous aluminum oxide membranes made from two-
step anodization process have high pore density and high level of pore ordering. 
Typically the first step is carried  out  on  ~1µm   thick  aluminum  films  in  0.3M  oxalic  
acid solution at room temperature using Pt as a counter electrode. The anodization was 
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conducted under a constant voltage mode (40 V) for approximately 4 min.  Then the 
aluminum  samples  were  etched  in  0.3 M  phosphoric  acid  in  order  to  enlarge  the  
pore depth [ 6 ]. The pore size of AAO membranes can be controlled by changing 
phosphoric etching time as shown in Figure 1.1.   
    The working mechanism of the synthetic membrane is very simple: A membrane acts 
as a selective barrier, separating two different regions and allowing some matter to pass 
through, but not others [2]. Traditional synthetic membranes carry out simple passive 
transport under different driving forces such as pressure, concentration gradient, 
temperature etc., resulting in low selectivity and high energy consumption. Concentration 
polarization, which is concentration build-up phenomenon on the membrane surface 
caused by the different permeation rate of mixture components through the membrane, 
and membrane fouling are two other major challenges for these passive transport 
synthetic membranes [7].  
1.2 Biological Membranes  
 
Biological membranes, however, are highly complicated transporters that have the 
ability to actively pump specific chemicals or transport specific signals through the 
membrane channels at dramatic rate, which is very import for cellular function [8]. 
Biological membrane is composed of a bulk phospholipid bilayer with various imbedded 
protein in a fluid mosaic arrangement.  The transmembrane potassium channels can 
specifically regulate the transport of potassium by changing voltage, which are of vital 
importance in the returning the depolarized cell to a resting state [9]. Another example is 
nuclear pore complex regulating the transport of mRNA and proteins across the nuclear
10
. 
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Also, insects detect pheromones by transport stimulant odorant molecules through lipid-
coated nanopores. The waxy fluid lipid coated nanopores act as receptor chemistry on the 
surface of insect antennae, capturing and concentrating the pheromones ligand and 
delivering them to the inner pore tubules dispenser which can facilitate the transport of 
pheromones [11, 12]. Figure 1.2 shows one example of active transport process in cell 
membrane [13]. First, the molecules attach to the binding point of the transport protein in 
the cell membrane. The bottom of the transport protein is closed so that no other 
molecule can pass through the membrane. Second, ATP attached to the bottom transport 
protein to open it and deposit the molecule inside the cell. Finally, the transport reset to 
original state for next transport process. From this active biological membrane transport 
process we can see that the keys to biological protein channels are (1) selective receptor 
chemistry at the pore entrance, (2) a mechanism for fast fluid flow or mass-transport, and 
(3) signal chemistry at the exit side of protein to activate the channel [14, 15]. In 
particular, can we develop a platform that allows the sequential actuation of gatekeeper 
molecules to give active transport? 
1.3 Bio-inspired Membranes 
 
The advances in nanotechnology and synthetic biology make it possible to study and 
mimic biological membrane through integration of engineering and biology, which in 
turn can facilitate the understand of biology systems. Key to mimic biological pore is a 
nano-scale pore scaffold that can be easily modified with different chemistry.  Many 
different methods have been developed to create such nano-scale pore scaffold. Li and 
co-workers
16
 successfully created single nanopores in thin silicon nitride membrane using 
ion beam sculpting. Storm and co-workers [17] used electron beams to create sub-
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nanometer pore diameters. A 20 nm pore is initially created within silicon membrane 
using electron-beam lithography followed by anisotropic etching.  The pore is then 
further treated with thermal oxidation to shrink the pore to a single-nanometer resolution.  
However, this method is hard to produce large quantity of pores within the silicon 
membrane.  
Different types of bio-inspired nano-scale pores have been developed to mimic 
biological pores and channels. Single nanopore coated with lipid bilayer was recently 
reported to mimic lipid coated channels in olfactory system of insects, which can pre-
concentrate odorant molecules from the environment and transport deposit them inside 
the coated nanochannel (Figure 1.3) [12]. There are several advantages of this lipid 
coated SiN nanopores. First, absorption of non-specific binding molecules to the lipid 
coated membranes is minimal compared to bare membrane; Second, Biotoin groups can 
be attached to the lipid bialyer to specifically capture avidin-functional molecules. Lastly, 
the translocation speed of the molecules through the nanopore can be controlled by 
changing the viscosity of the lipid-bilayer. The nuclear pore complex consists of a very 
large protein channel that can be found at all eukaryotic cells. Nuclear pore complex have 
the ability to transport single strand DNA at an enhanced speed under the help of 
transport carrier.  Caspi and co-workers [18] modified porous membranes inside wall 
with polyisopro-pylacrylamide (pNIPAM) to mimic the nuclear pore complex, and 
demonstrated that single strand DNA moves much faster in the pNIPAM modified 
channel compared to bare channel.   
Importantly, studies have also been carried out to mimic ion channels. Ionic channel 
consists of membrane proteins that have the ability to facilitate the ion transport across 
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the membrane by regulating transmembrane voltage and steric binding.  The mechanism 
of ion transported through the channel is complicated. The ion channels consist of a 
single polypeptide that has four homologous domains. Every domain has six membrane 
spanning alpha helices including the voltage sensing helix, S4. The sensing helix has a 
high density of cationic peptides such that high positive potential (cation density) outside 
the cell repels the helix pushing it to block the channel.  To open the channel, the helix 
will undergo a conformational change to allow ion flow when the cell interior is 
depolarized. Nevertheless, many different biomimetic ion channels have been developed. 
Tian and co-workers [19] modified polymeric nanochannel with zinc finger peptide. 
Upon adding zinc ion, the zinc fingers fold to finger-like conformations, resulting in a 
pore diameter increase (Figure 1.4). Study has also been carried on artificial pH-
responsive ion channels. Yameen and co-workers [20] modified solid-state nanopores 
with pH-responsive poly(4-vinyl pyridine) brushes. The change of the solution pH will 
change the polymer conformation and thus resulting ‘on’ and ‘off’ state of these 
nanopores, which is monitored by current signal. This mimics the biological channel by 
switching from an “off” state to an “on” state in response to pH drop. 
Carbon nanotube (CNT) membranes also offer an exciting platform to mimic natural 
protein channels due to (1) enhanced fluid flow within CNT, (2) ability to place receptor 
chemistry at the entrance to pores, and (3) being conductive allowing for electrochemical 
transformation and application of electric field [ 21 , 22 , 23 , 24 , 25 ]. Monolayer 
‘gatekeeper’ activity to open and close pore entrances with charged ‘paddles’ 
demonstrated small ion rectification with applied trans-membrane bias, closely 
mimicking ion channels.  Biochemical-reaction induced switching of ionic transport 
7 
 
through CNT membranes was also shown to mimic biological membranes [26]. In this 
study, the pore entrances of CNT membrane were covalently functionalized with a 
desthiobiotin derivative that bind to streptavidin protein at one of 4 well-defined sites. 
The ionic flux through CNT membranes decreased upon pore blockage by streptavidin 
protein. The ionic flux was recovered by the addition of biotin solution, which is a 
stronger binding agent than desthiobiotin towards streptavidin, and released the protein 
hindrance at the pore entrance. Hinds and coworkers [27] also showed that synthetic CNT 
membranes can be used to mimicking protein channels regulated by phosphorylation 
enzymatic (ATP cycle) reactions at the pore entrance.  
1.4 Aluminum Oxide Membranes for Biopharmaceutical Applications 
 
There are large-scale applications in mimicking active transport of biological 
membranes such as drug delivery, chemical separations and sensing. Although CNT 
membranes shows great promising in mimicking the active transport of biological 
membranes due to fast fluid core and monolayer gate-keeper chemistry, the low porosity 
(~0.01%) limits its use in large-scale chemical separations. Aluminum Oxide (AAO) 
Membranes are commercial available membrane with high porosity (50%) and tight pore 
size control (+/- 20%) within a range of 20-200 nm.  The larger pore size of AAO 
compared to CNTs (1-7 nm i.d.) is a better size range when dealing with large proteins 
and other biomolecules ~10nm diameter. The membrane also exhibits low protein 
binding, has minimal auto-fluorescence, is nontoxic, and supports cellular growth 
(Whatman), thus offering an attractive platform for biopharmaceutical and biomedical 
applications.  
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Porous substrates such as AAO membranes have gained increased attentions for 
biosensor applications. Stephan and co-workers [28] recently reported a binding assay for 
small molecules based on the reflectivity change of a porous transparent film upon 
immobilization of absorbing substrates on the pore walls. Dhathathreyan [ 29 ] also 
reported the real-time monitoring of invertase activity immobilized in nanoporous AAO 
substrates. Immobilization of and trapping of invertase the porous wall structure was 
studied using confocal laser scanning microscopy showing excellent correlation with 
surface plasmon spectroscopy.  The enzymatic reactions were carried out in a continuous 
flow cell apparatus with high enzyme activity (4.49×10
5
 M
-1
 s
-1
) 
AAO membranes have also been extensively studied for protein purifications. 
Osmanbeyoglu and co-workers [ 30 ] reported the successful fabrication of AAO 
membrane with narrow pore size distribution (20-30 nm diameters) by anodizing 
aluminums films on silicon substrates. This membrane showed the ability to separate 
similar size proteins based on electrostatic interaction with the anionic membrane surface. 
Porous membrane absorbers are also attractive platforms for efficient affinity protein 
purifications. However, one major disadvantage of these membrane absorbers is that their 
low surface area causes low binding capacity compared to chromatography columns with 
micro-scale porous bead packing. Bruening and co-workers [ 31 ] modified AAO 
membrane with poly (2-hydroxyethyl methacrylate) (PHEMA) brushes, followed by the 
adding of NTA-Ni
2+ 
complex. This brush modified AAO membrane allows purification 
of polyhistidine-tagged ubiquitin (HisU) in less than half an hour with a binding capacity 
of 120 mg of HisU/cm
3
 of porous alumina membrane.  
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Pore size control and surface modification would enable enormous applications of 
AAO membranes in bio-separation and biosensor. Gold electroless plating on AAO 
membranes show promise for use as highly selective filters for membrane-based 
separations.  However, most of the work to date was focused on gold nanotubes 
fabrication by electroless deposition of gold within track-etched polymeric filtration 
membranes. Martin and co-workers have been exploring applications of gold nanotube 
membranes prepared via a template method [32, 33, 34, 35, 36]. These membranes were 
prepared by electroless deposition of Au within the whole channel of polycarbonate 
template membranes. Briefly, the template membrane was incubated with SnCl2 first to 
deposit Sn on the membrane. The membrane was then treated with AgNO3, followed by 
gold-plating solution. By carefully controlling the plating pH and plating duration, it’s 
possible to obtain uniform gold nanotube within the polycarbonate membranes. The 
outside diameter of gold nanotube is determined by the inside diameter of the 
polycarbonate template. The inner diameter of gold nanotube can be controlled by 
changing the electro-less plating at will. Using this gold nanotube membranes, Martin 
and co-workers demonstrated the size-based protein separation in Poly (ethylene glycol)-
Derivatized Gold Nanotubule Membranes33[33]. 
Despite the systematic study of gold nanotube within the track-etched polycarbonate 
filter, the track-etched suffered from very low porosity (<1%), resulting very low flux. In 
contrast, AAO membranes are very popular commercial available templates with high 
porosities (~50%). However, few studies [34] have been carried out on the electroless 
plating of gold within the pores of these membranes. This is because the current 
electroless plating method doesn’t work within AAO walls. Gold electroless plating on 
10 
 
the AAO membrane pore entrance and exit, however, hasn’t been studied [37].  Electro-
less plating on the pore entrance of AAO membranes (Figure 1.5) has several benefits. 
First, the surface of gold can be easily functionalized with different chemistry including 
selective receptor chemistry. Second, voltage can be applied on this gold electrode to 
facilitate the ion transportation within the AAO membrane with relatively high electric 
fields across the 60um thick film. Third, the pore size of AAO membrane can be easily 
controlled by changing the electro-less plating time onto the initial sputtered Au seed 
layer. Of particular importance is to tune the size of pores to match expensive/important 
targets such as proteins and enzymes. 
    The functionalization of AAO membrane pore entrance would enable numerous 
applications. Although it is difficult to have a precise monolayer at the pore entrance (as 
can be done in CNT membranes), the Au can be localized to the top 20 nm of the 
membrane surface and pore entrances by evaporation thin film deposition. The gold 
Electro-less plating reactions will only form on the sputtered gold seed. Electro-less 
plating [38] was accomplished in 50 mM pH 7.0 phosphate buffer containing 1.6 mM 
sodium gold (I) thiosulfate and 2.68 mM ascorbic acid. The oxidization and reduction 
reactions are given by 
 
 
1.5 Protein purification methods 
 
The history of protein purification can be dated back to 1789, when Antoine Foucroy 
first use precipitation method to separate substances from plants that are similar to egg 
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white. In 1840, Felix Hoppe-seyler reported the first crystallization of hemoglobin. Later 
in 1889, Franz Hofmeister also purified hen egg-white albumin through crystallization. 
Precipitation and Crystallization were the only available protein separation methods until 
the beginning of 20
th
 century [ 39 ]. These two methods still remain as important 
purification methods. Chromatography and electrophoresis methods were developed in 
the next decades. Chromatography is a separation and analysis method based on different 
interaction of substrates with the column matrix. Ionic exchange chromatography (IEC), 
hydrophobic interaction chromatography (HIC) and size exclusion chromatography (SEC) 
are three major chromatography methods used today for three-stage purification strategy 
(Capture, intermediate purification and polishing).  
With the development of biotechnology, genetically engineered therapeutic proteins 
are becoming more important for bimolecular treatment. The ability to fuse affinity tag 
into the recombinant protein promotes the development of affinity chromatography (AC).  
Poly-histidine, as the most often used tag, is often fused into the recombinant protein for 
quick and efficient purification from cell crude lysate using immobilized metal ion 
affinity chromatography. In 1982, fast protein liquid chromatography (FPLC) was 
introduced by Pharmacia (Now GE healthcare), which greatly benefits the small-scale 
laboratory protein purification for various studies.  Generic purification methods based on 
affinity tag fused into the protein has revolutionized protein purification, making today’s 
protein purification easily and efficiently. However, for the clinical protein study, affinity 
chromatography alone cannot provide sufficient purity, and other polishing steps are 
needed such as IEC, HIC and SEC. Also, protein stability after purification needed to be 
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considered as this is very important for formulation study. In the following paragraphs, 
various chromatography methods will be discussed in detail. 
1.5.1 Ionic Exchange Chromatography 
 
Ionic exchange chromatography separates proteins based on the different surface 
charges [40]. Typically, targeted protein will bind to the charged chromatography media 
and be retained for subsequent release. However, impurity can bind to the charged 
chromatography media and need to be removed. Proteins consist of various amino acids 
which has different pKa. These amino acids will determine the finial structure of proteins 
and also contribute to the net surface charges. Proteins with different surface charges will 
have different interactions with the charged chromatography.  
Every protein has different isoelectric point (pI) due to different component of amino 
acids. When the pH of the solution is higher than the pI, protein will show negative 
charge and can bind to positive charged chromatography. Here the IEC is called cation 
exchange chromatography.  When the pH of the solution is lower than the pI, protein will 
show negative charge and can bind to negative charged chromatography. Here the IEC is 
called anion exchange chromatography.  When the pH of the solution is equal to the pI, 
protein will have no change and will not interact with the chromatography medium. 
There are usually four steps in an IEC process. First, the chromatography medium is 
equilibrated with start buffer; in the second sample loading step, charged proteins bind to 
the ionic groups of the medium and get concentrated. Impurities won’t bind to the 
medium and are eluted after sample injection. Third, the ionic strength of the solution is 
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increased to compete with the bound proteins and release the protein. This can be 
achieved through gradient elution or step elution. Finally, the column is re-equilibrated.  
IEC is a very powerful protein purification method that can be used in any part of 
multi-step purification procedure. In a three stage purification strategy, IEC is often used 
in the first step to remove any other impurities and opposite charged proteins followed by 
HIC and SEC. 
1.5.2 Hydrophobic Interaction Chromatography 
 
Hydrophobic interaction chromatography separates proteins based on interactions 
between protein and hydrophilic matric surface [41]. HIC is often used in the second step 
of the three-stage purification strategy (Intermediate purification). After the first stage-
Capture (often with IEC), HIC is often used to remove other bulk contaminants.  
There are also four steps during the HIC purification. First, the chromatography 
medium is equilibrated with start buffer; in the second sample loading/application step, 
proteins bind to the hydrophobic medium surface in high salt concentration (typically 1 to 
2 M ammonium sulfate). Third, the ionic strength of the solution is lowered release the 
bound protein. This can be achieved through gradient elution or step elution. Finally, the 
column is re-equilibrated with low ionic strength buffer. 
1.5.3 Size Exclusion Chromatography 
 
Size exclusion chromatography separates proteins based on protein molecular size 
difference [ 42 ]. Unlike HIC and IEC, SEC is a non-binding separation method. 
Separation is based on the different travel rate through the chromatography medium. The 
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chromatography medium is composed of porous beads.  Small protein can diffuse into 
these porous beads pore thus taking longer time to travel through the column. Large 
proteins can’t diffuse into these porous beads pore thus taking lower time to travel 
through the column. As a result, large proteins elute first and small proteins elute last. 
Due to the non-binding separation mechanism, the protein peak will get broad as they 
pass through the column. Sample injection volume need to be kept small to achieve high 
separation resolution. No buffer change is needed in SEC purification process. Only one 
buffer was used in the SEC separation process. SEC is often used for desalting and buffer 
exchanges.   Also, SEC can be used in the last step of the three-stage purification strategy 
(polishing). 
1.5.4 Immobilized metal ion affinity chromatography 
 
Immobilized metal ion affinity chromatography (IMAC) separates proteins based 
specific affinity binding between target protein and metal ion (Ni
2+
,
 
Cu2
2+
,
 
 Zn
2+
,
 
Co
2+
) 
modified matrix [43].  Target protein will specifically bind with the matric surface 
through chelation binding, while other impurities will be washed away during the sample 
load step. In current therapeutic protein production, target protein can be genetically 
modified to include a poly-histidine tag at a terminal position away from active sites.  
Critically this allows an engineered marker that forms a strong chelation bonding with 
Ni
2+
, to give a highly selective protein purification process among proteins of similar size 
and charge.  
There are usually four steps in an IMAC process. First, the chromatography medium is 
equilibrated with ~20 mM imidazole buffer; in the second sample loading step, Poly-
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histidine tagged protein bind to the metal ion groups of the medium and get concentrated. 
It should be noted that ~20 mM imidazole concentration is used in the loading sample 
solution to eliminate non-specific binding. Impurities won’t bind to the medium and are 
eluted after sample injection. Third, 200-500 mM imidazole solution is used to elute the 
bound protein. This can be achieved through gradient elution or step elution. Finally, the 
column is re-equilibrated.  
1.6 Enzyme immobilization 
 
    In addition to separations, membranes can be used as supports for catalyst giving 
simultaneous separations and reactions in a field known as ‘membrane reactors’.  Of 
particular importance are enzyme catalysts that have seen broad use in waste water 
treatment
44
.  Biological enzymes can do far more complex chemistry than man-made 
systems due to their highly complicated structure. In spite of the great opportunity of 
biological enzyme in drug discovery, they are relatively fragile/unstable, expensive and 
hard to reuse.  This prevents their wide use in industry processes. Immobilization of 
enzyme is one of the most important engineering strategies to address these limitations, 
but must not de-nature the activity of the enzyme when bound to the surface. Both 
carrier-free and carrier-based immobilization technology have been used for enzyme 
immobilization. Carrier-free immobilization, mostly cross-linking of an enzyme, can 
result in the loss of enzyme activity due to the intensive modification of residues by 
glutaraldehyde cross-linker [45,46]. Non-covalent adsorption on solid support is the 
easiest immobilization method. However, the supported-enzyme is prone to leach into 
bulk solution during the catalytic reaction. Carrier-based immobilization through covalent 
bond is much more stable. Generally, many lysine residues on the protein surface can be 
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tethered to the functionalized solid surface. These multipoint covalent bonds can increase 
the rigidity of the immobilized enzyme, which, on the other hand, increase the risk of 
changing the active sides of enzyme [47]. Enzyme immobilization using affinity tags is a 
better way to maintain enzyme stability on the solid support and retain the enzyme 
activity at the same time [48]. One example is the genetically modification of N-terminus 
of the enzyme with histidine tag, which has little influence on the activity of enzyme. 
1.7 Cell electroporation 
 
    Another area of membrane application outside of separations and reactions, is the 
interaction with living cells.  In particular the delivery of cDNA, siRNA, proteins or 
small drugs into living human cells plays a critical role in gene therapy, tissue 
engineering, recombinant protein expression and other bio-chemical treatments [49, 50]. 
However, current transfection methods have hindered their use for clinical and medical 
research applications due to their inefficiency in promoting target molecule uptake and 
toxicity. Chemical transfection using calcium phosphate precipitate, liposome and 
peptides have low efficiency and are often limited to certain cell types with specified cell 
size and shape [51, 52, 53]. Viral vector transfection is considered a more efficient 
transfection method [54, 55, 56]. However, viral vectors can cause serious immune 
response in the human body [57]. Moreover, the viral vector can’t be effectively used in 
the patient again after a failed trial, because the body will recognize it. Due to the 
inefficiency, toxicity, immunogenicity and inflammatory response of current transfection 
methods, an effective and less invasive gene therapy and molecular delivery techniques 
are of great interest to biological and biomedical researchers [58]. 
       As a safer and more efficient physical process, electroporation has been widely used 
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for introducing biomolecules into cells [59, 60, 61, 62]. Electroporation is the process of 
using an electric field to create temporary pores in the phospholipid-bilayer of the cell 
[63]. These temporary pores allow the passage of molecules through the cell membrane 
into the nucleus.  
    There are two kinds of electroporation technique-Irreversible electroporation and 
reversible electroporation. Irreversible electroporation is a tissue ablation technique using 
short and strong electric field to permanently damage the cell membrane. Reversible 
electroporation is the process of using an electric field to create temporary pores of the 
cell to allow the passage of molecules into the nucleus. Typically, electroporation 
threshold is between 150-400 V/cm. 
   Traditionally, cell electroporation is performed by placing two plate electrodes in a 
fixed-volume cuvette under high electric field [64]. However, this method can only 
perform limited amount of cells in each trial. Additionally, this approach requires high 
voltages (often >100V) to be applied across the electrodes to generate the desired electric 
field (150-424V/cm) [65] due to the long distance between the two electrodes in the 
cuvette.  This high voltage applied often results in sudden changes in local pH and 
temperature around the cells leading to their necrotic death. Lastly, this approach requires 
large amount of expensive-to-produce transfection reagents that are diluted in the flow 
solution. Desired electroporation device should operate at a low voltage to get high 
viability, and operate in a flow-based continuous process to achieve high throughput. 
Particularly promising was the use of micro-patterned PDMS holes on Anodized 
Aluminum Oxide (AAO) membranes to concentrate electric fields within the hole 
between distant electrodes, thereby reducing effective electroporation voltage to 9V with 
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greater than 80% cell viability of adherent cells 
66
However, there is very limited 
application for the genetic modification of adherent cells since the cells would have to be 
removed, transfected, and returned into the patient.  More promising is to target mobile 
circulating cells, such as white blood cells. In this case a micro-fluidic channel would 
have to be thin enough to promote intimate contact of the cell with the electrode as it 
flowed across the membrane surface, which would serve to minimize the distance 
between target molecules and the cell membrane during electroporation.  
1.8 Dissertation outline 
 
The primary goal of this dissertation is to invent new active membranes based on nm-
scale electrode geometries at membrane pore entrances and exits for biopharmaceutical 
applications. This is divided into three major topic areas: 1) protein separation with 
voltage pulse cycles, 2) enzyme immobilization and activation at pore/electrode surfaces 
and 3) cellular electroporation and electrophoretic injection at membrane pore electrode 
entrances. Chapter 2 and 3 will discuss protein purification using active membrane 
electrode system with voltage pulse cycles. Chapter 4 will present enzyme 
immobilization and activation at the membrane electrode surface. Chapter 5 will cover 
the cell electroporation using membrane electrode-microfluidic system. Chapter 6 
provides the conclusion for this dissertation. 
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Figure 1.1 SEM image of the AAO  membrane  with  0.1M H3PO4  at different etching 
time. (A) 60min (B)75min (C)90min (D) Cross section of C. (Reprinted with permission 
from Ref. [6]) 
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Figure 1.2 Active Transport process through cell that shows sequential actuations of 
gatekeeper chemistry. (Reprinted from ref. [13]) 
  
 
Active transport process 
1. Soluble molecules 
2. Transport protein 
3. Binding region 
 
4. Soluble molecules attach to the binding 
point of the opened transport protein in 
the cell membrane. 
5. ATP transmits phosphate to the 
transport protein. 
6. The phosphorized transport protein 
opens and changes shape so as to 
deposit the soluble molecules inside the 
cell. 
7. The phosphate separates from the 
protein by assuming its original form. The 
stage is now set for another soluble 
molecule to be transported. 
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Figure 1.3 Bio-inspired synthetic nanopores with bilayer-coated fluid walls.(a) Cross-
section of one sensillum in the antenna of the silk moth Bombyx mori. (b)Drawing to 
scale, showing a synthetic, lipid-coated nanopore in a silicon nitride substrate. (Reprinted 
with permission from Ref. [12]) 
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Figure 1.4 Illustration of the zinc fingers immobilized single nano-channel. In the 
absence of Zn
2+
, the zinc fingers in the nano-channel present unfolding structures; after 
Zn
2+ 
binding, the zinc fingers gold to finger-like conformations, yielding an increase of 
the effective channel diameter. (Reproduced with permission from Ref. [19]) 
 
 
23 
 
 
Figure 1.5 SEM images of bare AAO membrane and gold plating AAO membrane (a) 
Top view of bare membrane. (b) Cross section of bare membrane. (c) Top view of gold-
coated membrane. (d) Cross section of gold-coated membrane. The achievable electric 
field can be calculated by E=V/L, where V is the applied voltage on the membrane 
surface and L =60 µm is the membrane thickness. 
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Chapter 2 : Dynamic Electrochemical Membranes for Continuous Affinity Protein 
Separation 
 
This chapter is based on the manuscript: Zhiqiang Chen, Tao Chen, Xinghua Sun, Bruce. 
J. Hinds. ‘Dynamic Electrochemical Membranes for Continuous Affinity Protein 
Separation’, Advanced Functional Materials, in press 
 
2.1 Introduction 
 
  Genetic modification of a host cell to produce complex biomolecules is the critical route 
to bio-pharmaceutical production [67, 68, 69]. However, the separation of the desired 
protein from the myriad in living systems is the most costly and complicated step. The 
high cost of downstream purification of genetic protein expression hinders the wide-
spread use of therapeutic protein treatments with an example prophylactic replacement 
therapy being greater than $100,000 per patient per year.  Even with current advances in 
automated separation technology, 80% of the total cost of urokinase production is in 
purification [ 70 ]. The ability to genetically add poly-histidine tags to recombinant 
proteins enables affinity purification by immobilized metal ion affinity chromatography 
(IMAC) [71], which is the dominate separation method. However, IMAC suffers from 
limitations of long intra-particle diffusion time, high pressure drops, difficulties in 
packing large columns, column regeneration, non-specific binding, high cost and long 
binding/purge cycles [72].  The ideal separation method would be to have a selective 
membrane that could actively pump selected proteins across a barrier in a continuous 
process.  Traditional polymeric ultrafiltration membranes have been studied for protein 
separation/purification [73, 74], however pore size is difficult to control and manipulate, 
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leading to modest selectivity between similar proteins. Track-etching membranes and 
porous alumina membranes have precise pore size [75, 76] and Au plating has been 
successfully used to tune pore size surface chemistry, and electrochemical activity [32, 
33]. In complex mixtures, many classes of proteins have similar size and surface charge, 
making selectivity an ongoing challenge. Indiscriminate flow induced fouling is still a 
major limitation in pressure driven membrane separation that needs to be addressed [77]. 
Applied electric field, instead of pressure across the thick nanoporous membranes [78, 79] 
have shown enhanced rates and rough charge density based separation. Ultrathin silicon 
membranes with ~10 nm thickness and 5 nm pore size have even been developed and 
show potential for protein separation [80] due to short path length and tight pore size 
distribution. However separations based principally on the basis of size and/or charges 
are not sufficient to isolate specific proteins from complex cell extracts.  Affinity 
nanoporous membranes with immobilized ligands within the pores have the ability to 
capture highly specific proteins from cell extracts. However the operation is similar to 
IMAC, requiring binding/release cycles. Compared to IMAC, the membrane have more 
efficient flowing mass transport to binding sites but several orders of magnitude less 
binding area [81].  
 Biological membranes are capable of selectively transporting chemicals at 
dramatically enhanced rates with precise chemical selectivity and thus bio-inspired 
membranes have various applications in sensing, drug delivery and chemical separations 
[8, 82]. To mimic this natural biological system, the membrane platform should have 
receptor chemistry at the pore entrances acting as gatekeeper that can specifically capture 
and concentrate the affinity protein, and a driving force to pump protein across the 
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membrane barrier.  Here we report an active membrane system based on nm-scale 
electrodes that allow voltage pulses for sequential affinity protein binding and 
release/pumping cycles.  In particular the pore entrance is designed to have specific 
bound proteins, during both cycles, which block the pore from undesired protein transport 
across the membrane. 
 
2.2 Experimental details  
 
2.2.1 Reagents and Materials. 
 
   20nm Anodic Aluminum Oxide (AAO) membranes (60 µm thick) were obtained from 
Whatman (GE Healthcare). These AAO membranes are asymmetric with a bulk pore 
structure comprised of 200 nm diameter straight channels and a thin porous layer at the 
top with a diameter of 27 nm. The porosity was ~40-60%. Gold (I) thiosulfate (Alfa 
Aesar) was used to electro-less deposit gold electrodes at the entrance and exits of these 
membranes. NiCl2, Nα, Nα-Bis(carboxymethyl)-L-lysine (NTA, Sigma Aldrich) and 
Ascorbic acid (EM Science) were used as received. Bovine serum albumin (BSA, pI=4.9, 
MW=67 000) was purchased from Sigma Aldrich and used as received. Texas red 
conjugated BSA was purchased from Life Technologies Aldrich and used as received. 
His-tagged green fluorescence protein (His-GFP, pI=5.7, MW=28 000) was obtained 
from Millipore and used as received.  Purified water was prepared using a Millipore 
Milli-Q water purification system with 18.0 MΩ.cm resistivity. Regenerated cellulose 
membranes (molecular weight cutoff 3500) were purchased from Spectrum Laboratories, 
Inc. These regenerated membranes were rinsed with water for 1 h to remove glycerine 
before use. 
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2.2.2 Gold Electrodes/AAO membrane Preparation 
 
   Gold sputtering was first performed to create gold seed for the gold electro-less plating. 
Sputtering was performed with a Cressington Coating System (Ted-Pella) with calibrated 
quartz crystal monitor with background pressure of 0.02 mbar at 100W power supply. No 
intermediate wetting layer (i.e. Ti/TiO2) on Al2O3 was needed for seeding the Au layer. 5 
nm gold was sputtered on both the entrance and exit of AAO membranes at 1nm/min 
gold sputtering rate, which would deposit the diameter (20nm for the entrance and 200nm 
for the exit) distance down the pore. The gold Electro-less plating reactions will only 
form on the sputtered gold seed. Electro-less plating [38] was accomplished in 50 mM pH 
7.0 phosphate buffer containing 1.6 mM sodium gold (I) thiosulfate and 2.68 mM 
ascorbic acid. The oxidization and reduction reactions are given by 
 
 
The pore size can be tuned by controlling the electro-less plating time. The AAO 
membrane pore entrance size was measured by the analysis of images from a Hitachi S-
4300 Scanning Electron Microscope (SEM). 
2.2.3 Gold Electrodes/AAO Membrane Functionalization 
 
   As-prepared gold/AAO membranes were covalently grafted with Nα, Nα-
Bis(carboxymethyl)-L-lysine (NTA, Sigma Aldrich) by electrochemical oxidation [83]. 
The electrochemical grafting was performed in 0.1 M LiClO4 ethanol solution with 10 
mM NTA (Figure 2.11). Five cycles’ cyclic voltammograms scan from 0 V to 1.2 V with 
a 0.83 V oxidation peak of was carried out at 10 mV/s. After electrochemical oxidation 
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grafting, a cyclic voltammograms of 0.1 M in K3Fe(CN)6 in 0.1M PHOSPHATE solution 
(PH=7) was carried out to show increased surface resistance from grafting (Figure 2.12).  
The membrane was then thoroughly rinsed using de-ionized water and ethanol to dissolve 
any byproducts after the electrochemical oxidation grafting. The membrane was finally 
incubated in 0.1 M NiCI2 (Sigma Aldrich) for 30 min to form conjugate Ni-NTA surface.  
The chelate binding between Ni-NTA and His-tagged GFP is diagrammed in Figure 2.2.  
2.2.4 Bulk mobility of GFP and mobility of imidazole across the AAO membrane 
      
   The bulk mobility of GFP (7×10
-5 
cm
2
s
-1
 V
-1
) at PH 7 was measured by using a particle-
size and zeta-potential analyzer (Beckman Coulter Delsa(TM) Nano C Particle Analyzer) 
at 25℃. The experimental mobility of imidazole across the AAO membrane was studied 
using the setup in Figure 2.13 without the waveform generator. First a four-point standard 
curve of imidazole was drawn based on the 280nm UV-vis adsorption of imidazole at 
different concentrations. The imidazole mobility (µ) at PH 7 then can be determined by  
  
 
   
 , where   is the imidazole flux across the AAO membrane; E is the electric field 
across the AAO membrane and C is the feed imidazole concentration. The calculated 
imidazole mobility through AAO membrane is 14.4×10
-5
 cm
2
s
-1
V
-1
. 
2.2.5 Protein Separation Experiments 
 
   Two model proteins used for separation are His-GFP and BSA. His-tagged GFP has 
Eleven strands on the outside of cylinders form the walls of the structure. The cylinders 
have a diameter of 30 Å and a length of 40 Å.  BSA is also a cylinder with a diameter of 
55 Å and a length of 90 Å.  The setup for protein pumping process was shown in Figure 
2.13. In direct electrophoretic pumping, only the potentiostat (EA164 QuadStat, eDAQ 
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Pty Ltd), which is controlled by an e-corder 410 (eDAQ Pty Ltd) with Chart
TM
 software, 
was used and placed on the outer cell. Two Pt wires (one connected to the working 
electrode and the other one connected to the counter and reference electrode) were 
connected to the potentiostat and inserted into the outer electrolyte phosphate buffer (50 
mM, PH=7) solutions.  Two regenerated cellulose membranes (3500) were used in the 
experiment. BSA (67 000) and GFP (28 000) were restricted in the feed and permeate 
solution by the regenerated cellulose membranes (3500), which kept the proteins from 
oxidation or reduction by high voltages (6 V) generated at the Pt electrodes. At PH 7, 
both GFP and BSA were negative charged. The anode was in the Phosphate buffer 
adjacent to the permeate solution so that the negative charged proteins will be 
electrophoretically pumped to the permeate solution and the positively charged imidazole 
will be electrophoretically pumped to the feed solution from the permeate solution. When 
a 6 V was applied by the potentiostat, the voltage drop directly measured across the gold 
electrodes/AAO membrane was 0.3 V. Water underwent electrolysis and generated H
+ 
in 
the anode and OH
-
 in the cathode at 6 V in the outer compartments and phosphate Buffer 
was changed frequently to maintain the PH during the water electrolysis process. The 
volume of feed solution was ~1mL and the permeate solution was ~0.5 mL. The feed 
solution contained 7 µg/ml Texas red conjugated BSA and His-tagged GFP and the 
permeate solution contained 0.1-10 mM imidazole. In the pulse electrophoretic pumping 
process, a waveform generator (keithley 3390 50 MHz arbitrary waveform generator) 
was also used to generate 0.05 V on the gold/electrodes/AAO membrane during the 
binding cycle. The potentiostat was used to generate 0.3 V on the gold/electrodes/AAO 
membrane during the release/pumping cycle. The feed solution contained (1) 7 µg/ml 
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Texas red conjugated BSA and His-tagged GFP or (2)  1000 µg/ml BSA and 10 µg/ml 
His-tagged GFP; and the permeate solution contained 10 mM imidazole.  
2.2.6 Protein assay methods 
 
   The fluorescence intensity of His-GFP was measured using a fluorescence 
spectrophotometer (PerkinElmer LS 55 Fluorescence spectrometer), with an excitation filter 
of 395 nm and an emission filter of 509 nm.  The fluorescence intensity of Texas red 
conjugated BSA was measured with an excitation filter of 596 nm and an emission filter of 
615 nm. The fluorescence intensities of the experimental samples were compared to the five–
point standard curves of His-GFP and Texas red conjugated BSA. In the 1000ug/ml BSA and 
10ug/ml His-tagged GFP purification experiment, the total protein in the feed and permeate 
solution was expressed in mg/mL and compared with total protein concentrations expressed 
as BSA at λ = 280 nm in a spectrophotometer. The BSA standard curve for the permeate 
solution was drawn based UV-vis adsorption of BSA at the 280 nm in 10 mM imidazole 
solution since the UV-vis adsorption of 10 mM imidazole in the permeate solution will 
interfere with BSA. The total protein concentrations in the permeate solution ranged from 50 
to 1000 µg/mL, and the comparative relationship between total proteins and BSA was made 
through the five-point calibrated BSA standard curve. 
2.2.7 COMSOL Simulation 
 
   COMSOL 4.3 package (COMSOL, Inc, Burlington, MA) was used to model the 
electric field distribution across the asymmetric AAO membrane. A stationary 2D 
“Electric Current” mode under AC/DC model was created for the simulation. The model 
geometry is described as isosceles trapezoids with 0.2 µm bottom base and 0.02 µm top 
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base separated by 0.5 µm Al2O3 wall with a thickness of 60 µm. Phosphate-buffered 
saline is filled within the geometry pore and 2um above/below the membrane surface. 
The electric conductivity of the phosphate-buffered saline is 0.127 S/m. The electric 
conductivity of Al2O3 is 10
-5
 S/m. The boundary conditions used in our calculations were 
a constant potential drop (0.3 V) between the top phosphate-buffered saline solution (2um 
above the top membrane surface) and bottom phosphate-buffer saline solution (2um 
below the bottom membrane surface). The geometry was built with fine element mesh 
and computed. 
2.2.8 Numerical Modeling of Protein Pumping Membrane System 
 
   Microsoft Excel with Visual Basic Macros was used to numerically calculate 
concentrations in the model system.  A matrix of 240 x-values (0-120 µm, 0.5 µm steps) 
was initialized with boundary conditions and starting profiles.  A new matrix was made 
for the new time (previous time + time step).  Flux to/from neighbor cells into new matrix 
were calculated using Equation (1). The concentration change in the cell can be 
calculated from Equation (2) using the values in the matrix of the prior time step. After 
calculating each new concentration at x location, the prior time step matrix is overwritten 
with the newly calculated matrix and the cycle repeated until desired total time is reached 
using ‘For/Next’ loops in Visual Basic.  Time steps were chosen to be such that (D  )0.5 + 
cEµ   (characteristic diffusion length + electrophoretic distance) was much less than    
(typically 0.1*    to ensure numerical accuracy and stability.  
Detail physical parameters in the model:  
His-GFP bulk mobility: 7.5E-05 cmV
-1
s
-1
   
His-GFP bulk diffusion coefficient: 8.7E-07 cm
2
/s [84] 
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His-GFP diffusion mobility within the pore: 2.5E-06 cmV
-1
s
-1
   
His-GFP diffusion coefficient within the pore: 6.25-08 cm
2
/s (Einstein relation) 
Imidazole mobility: 1.44E-04 cmV
-1
s
-1
   
Imidazole diffusion coefficient: 3.6E-06 cm
2
/s (Einstein relation) 
Time step    : 5E-5 s 
(Dt)^0.5+ cEut = 4.3E-6cm (must be less than   ) 
Distance step    : 5E-5 cm 
Electric field within the membrane during pumping cycle: 50 V/cm 
Electric field outside the membrane during the pumping cycle 0.5V/cm 
Electric field within the membrane during repel cycle: 0.83 V/cm 
Electric field outside the membrane during the repel cycle 0 V/cm 
Bulk pore porosity (30.5 µm to 90 µm): 60% 
Porosity at the top thin porous electrode layer (30.0 to 30.5 µm): 10% 
Porosity at the top thin porous electrode layer after protein blocking (30.0 to 30.5 µm): 3% 
 
Initial conditions:  
0-30 µm: 10 ug/ml His-GFP 
30-120 µm:  0 ug/ml His-GFP 
0-90 µm: 0 mM imidazole   
90-120 µm: 10 mM imidazole 
   
Boundary conditions: 
Constant 10 µg/ml His-GFP at distance 0 µg for bulk feed solution. 
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Constant 0 mM imidazole at distance 0 µg for bulk feed solution. 
Constant 0 µg /ml His-GFP at distance 30-30.5 µm (above membrane surface) for 
binding cycle 
Cumulative amount of protein flux is saved as a variable stepwise 
The absorbed protein on the membrane surface is released in 200 time steps (0.01s) at 
t=12 s of pumping/release cycle 
Constant 10 mM imidazole at distance 120 µm of bulk permeate 
 
2.2.9 Numerical model validation 
 
    To validate whether our numerical model is correct, we did a comparison of one 
dimension diffusion results solved by our numerical model and compared to the known 
analytical solution of Fick’s second law. A simple case of diffusion with time t in one 
dimension from a boundary located at position x=0 with a constant concentration n(0)=10 
µg/mL is 
                
 
    
  
where erfc is the complementary error function, D= 8.70×10
-7
 cm
2
/s is the diffusion 
coefficient. One dimension diffusion plot solved by numerical model and complementary 
error function was shown in Figure 2.14. As shown in Figure 2.14, the results solved by 
numerical model and complementary error function overlap showing the accuracy of the 
numerical method with time and distance step.  The deviation of total cumulative flux (Q, 
area under curve) calculated numerically to the analytical solution was 6E-3%. 
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2.3 Results and Discussion 
 
The primary active area of this protein separation system is the nm-diameter electrode 
coated pore at the supported membrane pore entrance matched to the dimensions of 
proteins (~4nm).  This allows bound his-tagged proteins to block the pore from non-
selective protein transport.  Shown in Figure 2.1 is a scanning electron microscopy image 
of porous anodic aluminum oxide (AAO) membrane.  Cross-sectional SEM images 
shows that the bare AAO membranes are asymmetric with a bulk pore structure 
comprised of 200 nm diameter straight channels and a thin porous layer at the top with a 
diameter of 27 nm [85]. The top and bottom membrane surfaces are coated with 5nm of 
Au using sputtering deposition. This Au acts as a seed layer for the following Au electro-
less plating at the pore entrance region to reduce pore diameter to 10nm by controlling 
plating time [Figure 2.10].  The distance of the gold electrode down into the pore is also 
important since if the affinity chemistry is along the entire length of the pore, protein 
transport would be blocked by bound proteins.  The sputtering process, though not line-
of-sight, would be expected to deposit Au roughly 20 nm (pore diameter) distance down 
the pore allowing 3-5 layer proteins to be bound along the channel.  Nα, Nα-
Bis(carboxymethyl)-L-lysine (NTA) was covalently grafted onto the gold electrode by 
electrochemical oxidation of the primary amine as depicted in Figure 2.2 [86], which is 
more resilient than thiol-Au analog [87].  Cyclic-voltamograms of grafting process 
showed increased surface resistance [Figure 2.11, 2.12] confirming successful grafting.  
To demonstrate selective pore blockage by his-tagged green fluorescence protein (His-
GFP) and subsequently releasing of His-GFP by imidazole, the electrophoretic fluxes of 
BSA before His-GFP binding, with bound His-GFP and after imdizaole releasing were 
35 
 
studied and shown in Figure 2.3.  BSA was used to simulate complex protein mixtures, 
since having the same polarity as His-GFP represents the biggest challenge in 
electrophoretic-based separations. A seven-fold decrease of BSA flux was seen in the 
blocked case and recovered to 95% of the original flux after imidazole release.  Table 2.1 
shows the flux of His-GFP and BSA mixture (1:1) as a function of imidazole release 
agent.  At high imidazole concentrations (10mM) no binding/blocking was seen and both 
proteins are pumped through and no preferential separation was seen.  At 1mM imidazole 
partial blockage was seen with reduction in flux and modest selectivity.  With the lowest 
imidazole (0.1 mM) concentration both GFP and BSA fluxes were markedly reduced 
(factor of 3.4 and 30 respectively) and a selectivity of 7.7 was seen.  Two important 
inferences can be made from these series: 1) more than one layer of his-GFP is blocking 
the pore entrance since, with an open pore there would be a 50% chance of His-GFP 
binding or BSA passage.  This would give a maximum separation factor of 1.5 while 7.7 
was observed; 2) selective binding of His-GFP within pore, though enriching His-GFP, 
dramatically slows the flux, giving an inherent trade-off in flux vs selectivity that is only 
exasperated with dilute target concentrations found in common separations. 
The ideal separation system would be a two-cycle process with binding step followed 
by transport step, mimicking the function of cell wall transporters.  This can be achieved 
with electrophoretic pulses described in Figure 2.4 with 2 two-electrode pairs system 
(Figure 2.13).  During the first binding cycle, a small positive bias was applied on top Ni-
NTA/gold surface to attract anionic His-GFP and repel imidazole from the binding 
surface and pumps it to the permeate side.  The second electrode pair, outside of the 
regenerated cellulose membrane, applies a large voltage to pump cationic imidazole from 
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permeate side to the binding sites as well as pump the released anionic His-GFP across 
the membrane to the permeate side.  Figure 2.5 shows the fluorescence spectra of feed 
and permeate solutions, showing selective transport of His-GFP and a near background 
level signal of BSA.  The results of the pumping study are summarized in Table 2.2.  The 
first data column shows the control experiment with no binding chemistry and using only 
electrophoretic pumping (step 2).  In this case both proteins have high flux, comparable 
mobility, and lack of selectivity due to open channels.  In the second case, there is 
binding chemistry at the entrance and a 10mM supplementary of cationic imidazole in the 
permeate side that is pumped towards the binding site.  In this case the pumping rate 
decreased due to binding chemistry at the pore entrance thus reduced pore size but no 
selectivity is seen since both proteins are electrophoretically pumped through the 
membranes.  For the pulse pumping experiments in Table 2.2 we used a 0.05 V, 1s pulse 
for binding and a 0.3 V, 14 s pulse for pumping.  In this case a significant increase in His-
GFP flux was seen and a selectivity of 9.2 was observed.  It should be pointed out that 
this experiment had 100 fold higher BSA concentrations than His-GFP to more 
accurately simulate separations.  In such a case there is a 100-fold higher probability of 
BSA entering an open pore entrance after His-GFP is released.  The high separation 
factor indicates that the pore remains largely blocked, stopping BSA flux during the 
pumping cycle.  In the fourth data column, a 1:1 ratio of BSA/His-GFP is used to reduce 
the probability of BSA entering opened pore and selectivity is thus raised to 16 showing 
the validity of the active pumping separation system.  The pumping cycle time of 14s was 
chosen based on a conservative estimate of the required amount of imidazole would be 
the molar equivalent of 150mM routinely used in IMAC to elute His-GFP times the AAO 
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membrane volume (1.9×10
-3 
cm
3
).  With a 0.3 V measured potential drop across 
membrane electrodes (60 µm) and the experimental observed imidazole mobility of 
14.4×10
-5
 cm
2
s
-1
V
-1
 (see experimental section) a imidazole flux of 7.2×10
-8 
molcm
-2
s
-1
is 
calculate from the 10mM permeate solution, thus requiring 12.5 s to give 150mM 
equivalent in the pore volume. To improve efficiency of pumping cycle a valid model 
needs to be developed. 
The active membrane system is best modeled with a three-step process of 1) diffusion 
of target 2) pumping of imidazole to release target and 3) electrophoretic pumping of 
target to the permeate.  The three processes can be simulated numerically in 1 dimension 
by a combination of Fick’s 1
st
 law of diffusion and electrophoretic pumping shown in 
Equation (1). 
                  
  
  
                                                                  [1] 
Where J is flux per unit area, c is concentration, D is diffusion coefficient, and u is 
mobility, E is the electric field and    is the step width of simulation cell size (0.5um). 
The concentration change in the calculation cell is given by Equation (2) 
                                                             [2] 
Where    is numerical simulation time step (5x10-5s).  Jin is flux (/unit area) in from 
neighbor cells and Jout flux out to neighbors calculated from Equation (1).  Here rel is the 
relative porosity of calculation cell with respect to neighbor cell.  AAO membranes are 
asymmetric with 3% porosity at the protein bound site and 60% porosity in the membrane 
open pore structure. Pore size is shrinking as we approach the 20nm active pores and 
would thus expect increasing electric field due to increased resistance of smaller 
conducting cross-sectional area (see Figure 2.7, 2.8, 2.9).  However, due to the 
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electrophoretic pumping of imidazole into a smaller volume, the ion concentration 
increases the conductivity of the solution thereby reducing electric field.  Therefore we 
used constant electric field across the membrane in this simplified model.  At the 
boundaries between feed solution, protein binding site, and open membrane channels, the 
difference of net protein flux, due to changes in porosities, leads to the accumulation of 
imidazole at the binding site during electrophoretic pumping. Details of the Visual Basic 
simulation parameters can be found in the experimental section. Shown in Figure 2.6A-C 
are simulation of feed solution (0-30 µm), binding site (30.0-30.5 µm), bulk membrane 
(30.5-90 µm), and the permeate solutions (90-120um). Figure 2.6A shows the 1 second 
binding cycle depleting the target protein from feed solution following Ficks law. This 
results in 0.0033 µg of protein absorbed onto the 0.32 cm
2
 membrane area per 1s cycle.  
Figure 2.6A also shows the repulsion of imidazole at the binding site allowing target 
protein binding.  The initial concentration of imidazole (t=0) was the steady state profile 
after 1 cycle.  Figure 2.6B shows the numerical simulation of the release/pumping cycle.  
The imidazole is quickly pumped to a steady-state profile of high concentrations at the 
binding site.  According to Equation (2), the concentration increase at the binding side is 
primarily due to reduction in porosity from bulk pore side (60%) to the binding site (3%).  
The drop in imidazole concentration into the feed (at 0.003 cm) is primarily a result of 
the abrupt change in porosity. This simplified model used 0mM imidazole at 0 um as a 
boundary condition to represent a bulk solution sink, but the concentration at this point 
would increase with pumping time to near the imidazole source concentration.  However, 
most important is the imidazole concentration near the pore entrance (sub-micron scale).  
In the binding cycle, the imidazole is electrostatically pushed away from pore entrance 
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(figure 2.6(A)) and does not require a strong concentration gradient to the bulk value 0 
mM to achieve this. 
  For the protein pumping, the pore is blocked by bound proteins at pore entrance and 
only pumping of bulky target towards the permeate (to the right) can occur.  Depending 
on the release rate after imidazole accumulation, the concentration of protein in pores can 
exceed feed solution.  In this case, the protein was released at 12 s and 
electropohoretically pumped into the channel.  During the next pumping cycle, that peak 
would be pumped to the permeate for the full 14s of the cycle.  Figure 6C shows the 
predicted concentration profiles after 10 full cycles at the end of release/pumping cycle.  
Most important is that the first protein peak is pumped away from the binding site with 
cycle 2 and a steady state profile develops.  With its higher mobility, the imidazole 
concentration profile achieves steady state by the end of the first cycle. 
For the third step of pumping protein across the membrane, the observed His-GFP 
mobility across AAO membrane was 1.92x10
-6
 cm
2
s
-1
V
-1
, roughly 75 fold slower than 
imidazole (14.4×10
-5
 cm
2
s
-1
V
-1
).  Under 50V/cm field, the protein transit time across 
60um thick membrane is 62.5 s.  However, it is important to point out that the target 
protein does not have to exit the membrane during each cycle but be removed far enough 
from the binding site so as to not be pumped back during the binding cycle as seen in 
Figure 2.6C. The pumping distance of the target protein within the pore channel is 
directly proportional to the electric field times pumping duration.  In our case a factor of 
6 for electric field and 14 for pumping time would decrease the backwards pumping 
length during binding cycle by a factor of 84 compared to the forward pumping cycle.  
Our 1 s/14 s binding/pump cycle times was chosen from the estimates of the first two 
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steps.  Decreasing the overall cycle time can increase pumping rate proportionally, 
however require the knowledge of release rate kinetics, which is the object of future 
study. At present this technique is not suitable for cationic proteins with extreme pI. 
Large increases in pH (>pI), to render the protein anionic, would likely agglomerate 
protein mixtures.  An alternative binding system with anionic release agent would have to 
be used for cationic proteins to ensure opposite electrophoretic pumping direction. Also 
with complex Cell lysate mixtures additional pre-filtering would likely be required to 
prevent non-specific binding or agglomerate fouling. 
Overall pumping efficiency can be calculated from the observed His-GFP (4.5 µg) 
collected in permeate divided by the calculated His-GFP captured (0.0033 µg) times 
number of 1s binding cycles (2640 cycles)  giving 51.7% efficiency. This is also 
consistent with the premise that bound protein at the entrance is required to block the 
pore during pumping of released target.  This non-optimized system can be directly 
compared to commercial IMAC columns where this system requires 0.75cm
2
 of 
membrane area to have the same through put as a 1 cm
3
 IMAC
 
column used for 
laboratory scale separations. Ni-NTA Superflow Cartridge is a QIAGEN product for 
efficient affinity protein purification. Ni-NTA Superflow is comprised of Ni-NTA coupled 
to Superflow resin. QIAGEN Ni-NTA Superflow Cartridges are pre-filled with 1 ml Ni-
NTA Superflow and are ready to use for purification of 6xHis-tagged proteins using a 
liquid chromatography system (such as the ÄKTAdesign™ or FPLC™ System). The 
bead diameter is 60-169 µm and the recommended flow rate is 1 mL/min with maximum 
pressure around 5 bar. To purify 1ml 1000 µg/mL BSA and 10ug GFP mixtures using an 
Automated Chromatography System equipped with Ni-NTA Superflow Cartridge we 
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would use three steps, equilibration (10 min), loading/washing (20 min) and elution (10 
min) during the chromatography process. With a loading volume 50 µL, 20 runs are 
needed to separate 1ml volume of feed solution taking 10.3h.  In our pulsed experiment, 
GFP flux across the membrane is 1.29 µg.cm
-2
 h
-1
. In order to separate 10 µg GFP from 
the 1ml mixtures in 10.3 h, the needed membrane area is 10 µg /(1.29 µg .cm
-2
 h
-1
×10.3 
h)=0.75 cm
2
. With optimization of binding/release pulse and electrode geometry a 
promising active separation system from continuously producing bio-systems can be 
realized. 
2.4. Conclusion 
 
In conclusion, commercial available AAO membranes were successfully functionalized 
to mimic biological membranes for efficient protein separation. His-tagged proteins 
bound to the pore entrance block other proteins in a sequential/hopping manner, allowing 
selective transport. Electrophoretic pumping eliminates fouling associated with pressure 
flow, while pores closed by gatekeeper prevent fouling by other charged proteins. Pulsed 
electrophoresis binding/release/pumping cycle allows for a continuous protein separation 
process with low cost and high productivity. This would revolutionize protein separations 
where expressed proteins can be directly removed from fermentation baths with this 
membrane separation system. 
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Table 2.1Electrophoretic flux and Mobility of Texas red conjugated BSA and His-GFP 
through Ni-NTA-Gold/AAO membrane with different imidazole concentration in 
permeate side 
 
Imidazole concentration (mM) 10 1 0.1 
BSA flux (µg h
-1
 cm
-2
)         0.30 0.12 0.01 
His-GFP flux (µg h
-1
 cm
-2
) 0.28 0.19 0.082 
BSA effective mobility (10
-6
cm
2
 s
-1
 
V
-1
), ub 
1.97 0.79 0.07 
His-GFP effective mobility (10
-6
cm
2 
s
-1
 V
-1
), ug 
1.88 1.27 0.54 
Selectivity, S=ug/ub 
0.95 1.6 7.7 
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Table 2.2 Electrophoretic mobility and flux of BSA and His-tagged GFP proteins as a 
function of electrophoretic pumping cycle  
Pumping type Gold/AAO 
membrane,  
direct pumping 
a)
 
Ni-NTA-Gold/ 
AAO membrane,  
direct pumping 
a)
 
Ni-NTA-Gold/AAO 
membrane, pulse 
pumping 
a)
   
Ni-NTA-Gold/AAO 
membrane, pulse 
pumping 
b)
 
BSA flux (µg h
-1
 cm
-2
) 112.56 48.32 14.07 0.02 
His-GFP flux (µg h
-1
 cm
-2
) 0.73 0.34 1.29 0.32 
BSA effective mobility  
(10
-6
cm
2
 s
-1
 V
-1
), ub 
6.24 2.64 0.78 0.16 
His-GFP effective 
mobility  
(10
-6
cm
2 
s
-1
 V
-1
), ug 
4.08 1.92 7.2 2.54 
Selectivity, S=ug/ub 0.65 0.73 9.23 16 
a)
 Feed solution contains 1000 µg/mL BSA and 10 µg/mL His-tagged GFP; 
b)
 Feed 
solution contains 7 µg/mL Texas red conjugated BSA and 7 µg/mL His-tagged GFP. The 
imidazole concentration in the permeate side is 10 mM.  
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Figure 2.1SEM images of AAO membrane (left) and with electro-less plated Au on top 
surface (right) to control the pore entrance sizes 
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Figure 2.2 Schematic of Nα, Nα-Bis(carboxymethyl)-L-lysine electrochemical oxidation 
to functionalize gold layer and chelation bonding between NTA-Ni
2+
 and His-GFP 
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Figure 2.3 Electrophoretic pumping flux of BSA through functionalized AAO membrane 
before, after his-tagged GFP blocking and after imidazole release of His-GFP (1000 
µg/ml BSA feed concentration) (a); Schematic of AAO membrane blocked by his-tagged 
GFP pore and protein size drawn to appropriate scale (b)   
a b
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Figure 2.4 Schematic of pulsed electrophoresis process to pump His-tagged proteins 
across functionalized anodic aluminum membrane  
  
- +
Release/Pumping Cycle + Imidazole (+)
His-tag GFP (-)
BSA (-)
Binding/Repulse Cycle
NTA-Ni
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Figure 2.5 Fluorescence spectra showing the emission intensity of the baseline solutions, 
feed solutions and permeate solutions after pulse electrophoresis 
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Figure 2.6 Numerical simulation results of the pulse pumping cycles: (A) His-GFP 
binding and imidazole repulsion concetration during the 1s diffusion/repel cycle +0.05V 
at top electrode (x=30 µm); (B) His-GFP pumping and imidazole accumulation 
concentration profile during the 14s releasing/pumping cycle (50 V/cm across simulation); 
(C ) His-GFP and imidazole concentration profile at the end of pumping/releasing cycle 
as a function of total cycle number.  Imidazole profiles all overlap under cycle 10. 
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Figure 2.7 COMSOL simulation of electric field (EF) distribution across AAO 
membranes with 20 nm pores on top and 200 nm pores on the bottom. 2 µm gaps for top 
and bottom electrodes to simulate 300 mV voltage drop across the membrane with the 
external transmembrane electrodes present 
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Figure 2.8 COMSOL simulation of electric field (EF) distribution of the top narrow pore 
(20nm), magnification of Figure 2.7 
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Figure 2.9 COMSOL simulation of electric field (EF) distribution of the bottom large 
pore (200 nm), magnification of Figure 2.7 
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Figure 2.10 The average pore diameter of AAO membrane as a function of electro-less 
plating time 
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Figure 2.11 Cyclic Voltammograms on freshly gold/AAO membrane in 0.1 M LiClO4 
ethanol solution with10 mM NTA for the 1) first, (2) second, (3) three, (4) fourth, and (5) 
fifth cycles. Scan rate is 10 mv/s. Inserted is the apparatus for grafting 
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Figure 2.12 Cyclic Voltammogram of 0.1M K3Fe(CN)6 buffered by PH=7 PHOSPHATE 
solution on gold/AAO membrane before and after Nα, Nα-Bis(carboxymethyl)-L-lysine 
oxidation. Reference electrode is Ag/AgCl. Scan rate is 100mv/s. 
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Figure 2.13 Schematic of Electrophoretic pumping cell 
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Figure 2.14 One dimension diffusion plot solved by numerical method and the analytical 
solution using complementary error function.   
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Chapter 3 : Numerical study of Two-step Continuous Affinity Protein Separation 
with Nanometer-Scale Membrane Electrode Systems 
 
3.1 Introduction 
 
There is increased demand for more efficient recombinant protein purification methods 
due to the rapid advances in genetic engineering [88, 89]. More than 150 recombinant 
proteins have been produced for pharmaceutical use by recombinant DNA technology 
since the first well-known human insulin approved by Food and Drug Administration 
(FDA) in 1982 [90]. In order to simplify recombinant protein purification and detection, 
affinity tags such as polyhistidine or glutathione-S-transferrase (GST) are often fused to 
the recombinant protein [91]. As the most wildly used tags, polyhistidine can form 
specific chelation bond with Ni
2+
 complex, enabling affinity purification by immobilized 
metal ion affinity chromatography (IMAC)[ 92 , 93 ]. In a typical IMAC process, 
recombinant protein with His6-tag is retained within the Ni
2+ 
functionalized resin while 
other proteins are washed away. The bound recombinant protein is then eluted with 
concentrated imidazole. As dominate recombinant protein purification method, IMAC is 
favorable due to its mild operation condition [ 94 ]. However, IMAC suffers from 
limitations of long intra-particle diffusion time, high pressure drops, column regeneration, 
high cost and long binding/purge cycles [95, 96].  
Recently, extensive studies have been carried out on membrane chromatography [97, 
98] owe to its enhanced mass transport rate across the membrane pore compare to IMAC. 
However, the major challenge for membrane chromatography is low binding capacity due 
to low membrane surface area. Bruening and other researchers functionalize porous 
membranes with polymer brushes with multiple protein-binding sites to greatly increase 
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the binding capacity [99, 100]. However the operation of membrane chromatography is 
similar to IMAC, requiring multiple-step binding/release cycles. 
The needed process would be an automated and efficient recombinant protein 
purification process. In our previous paper [ 101 ], we developed a pulse pumping 
technique for the continuous separation of His-GFP from the BSA and His-GFP mixtures 
based on alternate binding/repel and releasing/pumping cycles. During the binding cycle, 
a small positive bias was applied on top Ni-NTA/gold surface to attract anionic His-GFP 
and repel imidazole from the binding surface and pumps it to the permeate side; During 
the releasing/pumping cycles, concentration of imidazole is controlled to keep the pore 
blocked while releasing proteins at the bottom edge of the electrode by applying a 
opposite bias in the outside compartments. However, the GFP releasing kinetic study and 
imidazole pumping process are needed to further optimize this pulse pumping system to 
increases protein separation efficiency and protein purity.  
This work describes the study of the pulse pumping conditions through the 
examination of GFP releasing kinetic and the numerically study of imidazole 
concentration during the pulse pumping cycles. The imidazole induced His-GFP 
releasing kinetic was first studied under a real-time fluorescence microscopy. His-GFP 
releasing kinetic data was then coupled with the numerically simulated imidazole 
concentration during the pulse pumping cycle to get the optimal pumping conditions, 
followed by experimental validation of the numerical study. A separation factor for GFP: 
BSA of 9.7 was achieved with observed GFP electrophoretic mobility of 3.1×10
-6 
cm
2 
s
-1
 
V
-1 
at 10 mM bulk imidazole concentration and 14s/1s pumping/repel duration. At higher 
bulk imidazole concentration (20 mM) and lower pumping duration (7s/1s pumping/repel 
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duration), high GFP electrophoretic mobility and low protein selectivity was seen due to 
inefficient pore blocking; At lower bulk imidazole concentration (5 mM) and higher 
pumping duration (23s/1s pumping/repel duration), low GFP electrophoretic mobility and 
high protein selectivity was seen due to longer pumping duration thus lower efficiency. 
The purification of His6-OleD Loki variant directly from crude E. coli extracts expression 
broth was demonstrated using the pulse pumping process, simplifying the separation 
process as well as reducing biopharmaceutical production costs. The enzymatic reactions 
showed that His6-OleD Loki was still active after purification. 
 
3.2 Experimental details  
3.2.1 Materials  
 
20 nm Anodic Aluminum Oxide (AAO) membranes (60 um thick) were obtained from 
Whatman (GE Healthcare). These AAO membranes are asymmetric with a bulk pore 
structure comprised of 200 nm diameter straight channels and a thin porous layer at the 
top with a diameter of 27 nm. The porosity was ~40-60%. Gold (I) thiosulfate (Alfa 
Aesar) was used to electro-less deposit gold electrodes at the entrance and exits of these 
membranes. NiCl2, N-[Nα,Nα-Bis(carboxymethyl)-L-lysine]-12-
mercaptohexadecanamide (NTA) (Sigma Aldrich) and Ascorbic acid (EM Science) were 
used as received. Bovine serum albumin (BSA, pI=4.9, MW=67 000) was purchased 
from Sigma Aldrich and used as received. Texas red conjugated BSA was purchased 
from Life Technologies Aldrich and used as received. His-tagged green fluorescence 
protein (His-GFP, pI=5.7, MW=28 000) was obtained from Millipore and used as 
received. Uridine Diphosphate (UDP), UDP- α - D –glucose, 2-chloro-4-nitro-phenyl-β-
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D-glucopyranoside (PNP-Glc),4-methylumbelliferone (4-Me-Umb), Vancomycin 
aglycon were purchased from were purchased from Sigma-Aldrich (St. Louis, MO, USA) 
or New England Biolabs (Ipswich, MA, USA). Purified water was prepared using a 
Millipore Milli-Q water purification system with 18.0 MΩ.cm resistivity. Regenerated 
cellulose membranes (molecular weight cutoff 3500) were purchased from Spectrum 
Laboratories, Inc. These regenerated membranes were rinsed with water for 1h to remove 
glycerine before use. 
3.2.2 His-GFP releasing kinetic study 
 
Glass cover slips pre-cleaned with KOH were immersed in 0.01% acetic acid 
containing 2% (vol/vol) 3-glycidyloxypropyl-trimethoxysilane (Sigma-Aldrich) for 3h at 
90°C and washed with water. The glass was incubated in 0.01 M NaHCO3 (pH 10.0) 
containing 50 mM Nα,Nα-Bis(carboxymethyl)-L-lysine hydrate (Sigma-Aldrich) for 16 h 
at 60°C and washed with water. Then, the glass was incubated in 10mM NiCl2 and 5mM 
glycine (pH 8.0) for 2 h at room temperature, washed with water, and stored in water 
until use. UV activated glue was used to adhere the functionalized coverslips to a 35mm 
Petri dish with an opening in the center to construct a dish with the functionalized 
ded to the 
coverslips and allowed to incubate for 30 minutes. The dish was then rinsed with 
phosphate buffered saline to remove unbound GFP. After removal of excess GFP, a small 
amount of buffer was added to each dish to keep solution on the coverslip. Samples were 
imaged with objective style total internal reflection fluorescence (TIRF) microscopy.  
GFP bound to the surface of the functionalized coverslip via nickel NTA were excited 
with a 488 nm DPSS laser (1.05 W/cm
2
) through the objective (Olympus, 1.49NA 60xoil 
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immersion).  Excitation light was directed toward the objective using the appropriate 
dichroic and the same dichroic directed emission light through the appropriate filter to an 
electron multiplying charge coupled device (EMCCD) (Andor iXon Ultra 897). To obtain 
total internal reflection (TIR), the laser was focused on the back aperture of the objective 
lens and the angle was adjusted using a stepper motor to translate the beam laterally 
across the objective lens. An auto-focus (Olympus, Model: IX2-ZDC2) was employed to 
keep the focus constant and minimize focal drift. A buffered solution of imidazole was 
added at time zero and then the fluorescence intensity was measured continuously for 120 
seconds with a 200 ms frame rate.  Fluorescence intensity was collected independently 
for each coverslip which were exposed to varying concentrations of imidazole. The decay 
curve of intensity versus time was constructed to determine the rate of departure of GFP 
from the surface. The photobleaching rate was determined by continuously collecting 
images of the fluorescence intensity in the absence of imidazole during laser excitation. 
The decay in the fluorescence intensity due to photo bleaching was used to correct the 
fluorescence decay curve due to departure of GFP from the substrate surface. 
3.2.3 Gold Electrodes/AAO membrane Preparation 
 
    The membrane/electrode preparation was same as previous study [101]. Briefly, gold 
sputtering was first performed to create gold seed for the gold electro-less plating. 
Sputtering was performed with a Cressington Coating System (Ted-Pella) with calibrated 
quartz crystal monitor with background pressure of 0.02 mbar at 100W power supply. No 
intermediate wetting layer (i.e. Ti/TiO2) on Al2O3 was needed for seeding the Au layer. 5 
nm gold was sputtered on both the entrance and exit of AAO membranes at 1nm/min 
gold sputtering rate, which would deposit the diameter (20 nm for the entrance and 200 
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nm for the exit) distance down the pore. The gold Electro-less plating reactions will only 
form on the sputtered gold seed. Electro-less plating
38
 was accomplished in 50 mM pH 
7.0 phosphate buffer containing 1.6 mM sodium gold (I) thiosulfate and 2.68 mM 
ascorbic acid. The oxidization and reduction reactions are given by 
 
 
The pore size can be tuned by controlling the electro-less plating time. The AAO 
membrane pore entrance size was measured by the analysis of images from a Hitachi S-
4300 Scanning Electron Microscope (SEM). 
3.2.4 Gold Electrodes/AAO Membrane Functionalization 
 
NTA Self-assembled [102] monolayer was prepared by incubation of gold with 1 mM 
NTA ethanol solution at room temperature for 24h followed by rinsing with ethanol for 3 
min and dried under N2 stream. The membrane was incubated with a 0.5M NiCl2 aqueous 
solution for 24 h at room temperature followed by rinsing with Milli-Q water for 3min 
and dried under N2 stream. 
3.2.5 Protein Separation Experiments 
 
    Two model proteins used for separation are His-GFP and BSA. His-tagged GFP has 
Eleven strands on the outside of cylinders form the walls of the structure. The cylinders 
have a diameter of 30 Å and a length of 40 Å.  BSA is also a cylinder with a diameter of 
55 Å and a length of 90 Å.  The setup for protein pumping process was shown in Figure 
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3.15. In direct electrophoretic pumping, only the potentiostat (EA164 QuadStat, eDAQ 
Pty Ltd), which is controlled by an e-corder 410 (eDAQ Pty Ltd) with Chart
TM
 software, 
was used and placed on the outer cell. Two Pt wires (one connected to the working 
electrode and the other one connected to the counter and reference electrode) were 
connected to the potentiostat and inserted into the outer electrolyte phosphate buffer 
(50mM, PH=7) solutions.  Two regenerated cellulose membranes (3500) were used in the 
experiment. BSA (67 000) and GFP (28 000) were restricted in the feed and permeate 
solution by the regenerated cellulose membranes (3500), which kept the proteins from 
oxidation or reduction by high voltages (6 V) generated at the Pt electrodes. At PH 7, 
both GFP and BSA were negative charged. The anode was in the Phosphate buffer 
adjacent to the permeate solution so that the negative charged proteins will be 
electrophoretically pumped to the permeate solution and the positively charged imidazole 
will be electrophoretically pumped to the feed solution from the permeate solution. When 
a 6 V was applied by the potentiostat, the voltage drop directly measured across the gold 
electrodes/AAO membrane was 0.3 V. Water underwent electrolysis and generated H
+ 
in 
the anode and OH
-
 in the cathode at 6 V in the outer compartments and phosphate Buffer 
was changed frequently to maintain the PH during the water electrolysis process. The 
volume of feed solution was ~1ml and the permeate solution was ~0.5 mL. The feed 
Texas red conjugated BSA and His-tagged GFP and the 
permeate solution contained 0.1-10 mM imidazole. In the pulse electrophoretic pumping 
process, a waveform generator (keithley 3390 50 MHz arbitrary waveform generator) 
was also used to generate 0.05 V on the gold/electrodes/AAO membrane during the 
binding cycle. The potentiostat was used to generate 0.3 V on the gold/electrodes/AAO 
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Texas 
red conjugated BSA and His-tagged GFP.  
3.2.6 Protein assay methods 
 
    The fluorescence intensity of His-GFP was measured using a fluorescence 
spectrophotometer (BioTek
®
 Synergy H1 Hybrid Reader), with an excitation filter of 395 nm 
and an emission filter of 509 nm.  The fluorescence intensity of Texas red conjugated BSA 
was measured with an excitation filter of 596 nm and an emission filter of 615 nm. The 
fluorescence intensities of the experimental samples were compared to the five–point 
standard curves of His-GFP and Texas red conjugated BSA.  
3.2.7 Protein Expression 
 
    Protein purification protocol was the same as previous published methods101. Briefly, 
cell pellets from standard heterologous overproduction of OleD Loki in E. coli were 
collected by centrifugation (6,000 xg at 4 °C for 20 min), resuspended in 2.5 mL of 
chilled lysis buffer (20 mM phosphate buffer, pH 7.4, 0.5 M NaCl, 10 mM imidazole), 
and lysed by sonication (5 pulses of 1 minute each) in an ice bath. Cell debris was 
removed by centrifugation (10,000 g at 4 °C for 20 min) and in the resulting crude 
extracts was loaded into pumping system. 
3.2.8 HPLC method 
 
    HPLC was conducted with an Agilent 1260 system equipped with a DAD detector 
with a 250 mm x 4.6 mm Gemini-NX 5μm C18 column (Phenomenex, Torrance, CA, 
USA) and using a linear gradient of 1% B to 71% B over 30 min, 71% B for 5 min, 71% 
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B to 1% B over 1 min, 1% B for 4 min (Solvent A = 50 mM PO4
2-
, 5 mM 
tetrabutylammonium bisulfate, 2% acetonitrile [pH adjusted to 6.0 with KOH]; Solvent B 
= acetonitrile; flow rate = 1 ml min
-1
; A254 nm;). Regardless of method, HPLC peak 
areas were integrated with Star Chromatography Workstation Software (from Varian, 
Palo Alto, CA, USA) and the percent conversion calculated as a percent of the total peak 
area. 
3.2.9 Physical parameters for the numerical simulation 
 
His-GFP bulk mobility: 7.5E-05 cmV
-1
s
-1
   
His-GFP bulk diffusion coefficient: 8.7E-07 cm
2
/s   
His-GFP diffusion mobility within the pore: 2.5E-06 cmV
-1
s
-1
   
His-GFP diffusion coefficient within the pore: 6.25-08 cm
2
/s (Einstein relation) 
Imidazole mobility: 1.44E-04 cmV
-1
s
-1
   
Imidazole diffusion coefficient: 3.6E-06 cm
2
/s (Einstein relation) 
Time step    : 5E-5 s 
(Dt)^0.5+ cEut = 4.3E-6cm (must be less than   ) 
Distance step    : 5E-5 cm 
Electric field within the membrane during pumping cycle: 50 V/cm 
Electric field outside the membrane during the pumping cycle 1V/cm 
Electric field within the membrane during repel cycle: 8.3 V/cm 
Electric field outside the membrane during the repel cycle 0 V/cm 
Bulk pore porosity (10.5µm to 70 µm): 50% 
Porosity at the top thin porous electrode layer (10.0 to 10.5 µm): 10% 
Porosity at the top thin porous electrode layer after protein blocking (10.0 to 10.5 µm): 2% 
Initial conditions:  
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0-10 µm: 5 µg /ml His-GFP 
10-70 µm: 0 µg/ml His-GFP 
0-70 µm: 0 mM imidazole   
70-80 µm: 10 mM imidazole 
Boundary conditions: 
Constant 5 µg/ml His-GFP at distance 0 µm for bulk feed solution. 
Constant 0 mM imidazole at distance 0 µm for bulk feed solution. 
Constant 0 µg/ml His-GFP at distance 10-10.5 µm (above membrane surface) for binding 
cycle 
Cumulative amount of protein flux is saved as a variable stepwise 
During the pumping, imidazole reaches steady state concentration cycle in 3s. 
46% of absorbed protein on the membrane surface is then first quickly released in 2s. 
12% of the absorbed protein on the membrane surface is finally slowly released in 9s. 
Constant 10 mM imidazole at from 70-80 µm of bulk permeate 
 
3.3 Results and Discussion 
 
Nanometer-scale membrane electrode is the primary active area for the pulse 
pumping system. Gold sputtering followed by gold electro-less plating at the pore 
entrance was used to fine-tune the initial 27 nm AAO membrane pore size to protein-
scale pore size (~10 nm). This is important that His-GFP bound to the electrode can 
effectively block these protein-scale pores during the binding cycle (Figure 3.1), stopping 
other protein mixtures entering the electrode pore. Unlike previous electrochemical 
grafting of Nα, Nα-Bis(carboxymethyl)-L-lysine onto the gold electrode, self-assembled 
monolayer technique was used to form more dense and uniform NTA on the electrode 
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surface. Ni
2+
 ligand that specifically captures His-GFP was then bound to the monolayer 
NTA for pulse pumping cycles. During the binding/repel cycles, a small voltage was 
directly applied on the electrodes surface to repel the imidazole from the electrode 
surface and capture the His-GFP at the same time; during the pumping/releasing cycles, a 
larger voltage was applied on the outside compartment to pump imidazole from the 
permeate side to the feed electrode surface to release the bound His-GFP and 
subsequently pump the His-GFP to the permeate side (Figure 3.2). To obtain the optimal 
pumping/releasing duration, it is necessary to study the His-GFP releasing kinetic by 
different concentration imidazole.  
To study the imidazole induced His-GFP releasing kinetic, a real-time fluorescence 
microscopy was used to record the His-GFP that is bound on Ni-NTA-Glass surface. The 
NTA chemistry was immobilized over glass surface according to established protocols 
[102] with minor modifications followed by Ni
2+
 attachment (Figure 3.3).   
His-GFP will then form covalent bond with the NTA-Ni chemistry on the glass. The 
amount of His-GFP bound on the Ni-NTA-glass can be determined by the fluorescent 
intensity recorded using the real-time fluorescent microscopy. When different 
concentration imidazole solution is poured into the glass container surface, His-GFP will 
be released from the Ni-NTA-glass surface at different rate and diffuse into bulk solution, 
which will be recorded as fluorescent intensity reduction under the fluorescent 
microscopy. The imidazole induced His-GFP releasing kinetic was shown in Figure 3.4, 
which is similar to the previous reported data [103]. Specifically, from Figure 3.4 we can 
see that 2 mM imidazole concentration is not high enough to release the bound His-GFP. 
As the imidazole concentration increases to 27 mM, it takes about 20s to the release half 
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His-GFP from the Ni-NTA-glass surface. Further increasing imidazole concentration will 
further lower the releasing time of His-GFP from the glass surface. It takes about 11s, 4s 
and 1s to release 60% of His-GFP from the glass surface using 54 mM, 109 mM and 169 
mM imidazole concentration respectively. To more realistically simulate the protein 
release process, the His-GFP releasing kinetic is manually divided into two parts-fast 
linear releases within the first 2 s and slow linear release after 2 s, as shown in Figure 3.5. 
The fast and slow release rates were estimated from Figure 3.4 using linear 
approximation within the first 2 s and after 2 s respectively.  
The imidazole concentration distribution during the pumping/releasing cycle is 
important to determine the pulse pumping condition. AAO membranes are asymmetric 
structure with a thin top layer of 27 nm diameters and bulk pore structure comprised of 
200 nm channel. The electro-less plating and bound of His-GFP on the top electrode 
entrance will shrink the original porosity from 50% to 10% and a final estimated 2% 
porosity after protein blocking, which will leads to the accumulation of imidazole at the 
binding site during electrophoretic pumping (Figure 3.2). Detailed imidazole 
concentration distribution during the pumping process can be by solving a combination of 
Fick’s 1
st
 law of diffusion and electrophoretic pumping shown in Equation (1) using 
Microsoft Excel with Visual Basic Macros. 
              
  
  
                                                     [1] 
Where J is flux per unit area, c is concentration, D is diffusion coefficient, and u is 
mobility, E is the electric field and    is the step width of simulation cell size (0.5µm). 
The concentration change in the calculation cell is given by Equation (2) 
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                                                             [2] 
Where    is numerical simulation time step (5x10-5 s). Jin is flux (/unit area) in from 
neighbor cells and Jout flux out to neighbors calculated from Equation (1).  Here rel is the 
relative porosity of calculation cell with respect to neighbor cell.           
                        A matrix of 160 x-values (0-80 µm, 0.5 µm steps) was 
initialized with boundary conditions and starting profiles. A new matrix was made for the 
new time (previous time + time step). Flux to/from neighbor cells into new matrix was 
calculated using Equation (1). The concentration change in the cell can be calculated 
from Equation (2) using the values in the matrix of the prior time step. After calculating 
each new concentration at x location, the prior time step matrix is overwritten with the 
newly calculated matrix and the cycle repeated until desired total time is reached using 
‘For/Next’ loops in Visual Basic. Time steps were chosen to be such that (D  )0.5 + 
cEµ   (characteristic diffusion length + electrophoretic distance) was much less than    
(typically 0.1*    to ensure numerical accuracy and stability. Detail physical parameters 
in the model can be found in the experiment section. 
Figure 3.6 shows the imidazole concentration distribution at different time during the 
pumping cycle.  The imidazole concentration at the 50% porosity cell next to the 2% 
porosity cell is calculated by Equation (3) 
                                                                            
                                   
    
   
                                                  [3] 
where      is old cell concentration,       is new cell concentration after time-step, 
            is the electric field within the membrane during the imidazole pumping 
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cycle,   is the diffusion coefficient and   is the electric mobility. Imidazole 
concentration in the permeate side is set to be constant 10 mM during the pumping 
process. As we can see from Equation 3, the incoming imidazole flux is much higher than 
the outgoing imidazole flux due to the porosity difference at the intersection, leading to 
imidazole accumulation at this area. With a 10 mM bulk imidazole concentration, the 
accumulated imidazole concentration is around 54 mM at the pore entrance electrode. 
The imidazole concentration reaches steady-state 54 mM in 3s. The high concentration 
imidazole at the entrance electrode is good for the quick releasing of bound protein. It 
should be noted that the boundary conditions during the simulation have great effect on 
the simulation results. Figure 3.16 is the imidazole simulation results with constant 
imidazole concentration at distance 120 µm and 5 unit 2% cells at the electrode entrance. 
Once bound protein is released from the entrance electrode, the high concentration 
imidazole needs to be repelled away for the subsequent His-GFP binding cycle. An 
opposite small voltage directly applied on two electrode surface is used to repel the high 
concentration imidazole to bulk concentration. 
    Figure 3.7 shows the imidazole concentration distribution at different time during repel 
cycle right after imidazole accumulated cycle. The imidazole concentration during the 
repel cycle is calculated by Equation (4) 
                                                                             
                                                                                         [4] 
Where              is the electric field within the membrane during the imidazole 
repelling cycle. As shown in Figure 3.7, the imidazole concentration at the 
electrode/membrane entrance is rapidly repelled to a concentration lower than bulk 
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imidazole concentration in 0. 5s. Steady-state imidazole concentration during the repel 
cycle at the electrode entrance is shown in Figure 3.8. 
    Combined the imidazole numerical simulation data with the His-GFP releasing kinetic 
data, it is now possible to predict the optimal pulse pumping conditions. Steady-state 
imidazole concentration during the pumping cycle at the electrode entrance is shown in 
Figure 3.9. The highest imidazole concentration at the membrane/electrode interface is 
roughly 5.4 times higher than the bulk imiadzole concentration. By changing the bulk 
imidazole concentration, the accumulation imidazole concentration at the electrode point 
will change accordingly. This simulated imidazole concentration at the electrode entrance 
can be coupled with the His-GFP releasing kinetic (Figure 3.3) to predict the optimal 
pumping durations. At low imidazole concentration, it will take longer time for the GFP 
releasing from the electrode, resulting low protein pumping efficiency; at high imidazole 
concentration, it will take shorter time for the GFP releasing from the electrode, resulting 
high protein pumping efficiency. However, if the imidazole concentration is too high, 
His-GFP can’t block the pore efficiently and other protein mixtures will enter the pore, 
resulting low purity His-GFP.  
Specifically, if the bulk imidazole concentration is 10 mM, the resulting imidazole 
concentration at the entrance would reach steady-state 54 mM concentration in 3 s. From 
Figure 3.3 we can see that it takes about 5 s, 11s and 20s respectively to release 50%, 60% 
and 70% of bound His-GFP from the Ni-NTA-Glass. So the estimated pumping duration 
would be 8 s, 14 s and 23 s since it takes about another 3 s to reach the steady-state 
concentration.  
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Table 1 summarized different pulse pumping conditions and the resulting protein 
separation efficiency and selectivity. When 10 mM bulk imidazole concentration was 
used, 8 s/1 s, 14 s/1 s and 23 s/1 s pumping/repel condition was experimental studied. A 
separation factor of 10.6 was seen with 8s/1s pumping/repel duration, however, the His-
GFP effective mobility was low (1.69×10
-6 
cm
2 
s
-1
 V
-1
) due to insufficient release of His-
GFP (50%) from the electrode entrance. A separation factor as low as 3.1 was seen with 
23 s/1 s pumping/repel duration, due to over release of His-GFP (70%) thus inefficient 
pore blocking. Both relative high His-GFP effective mobility and protein separation 
factor was seen when the pumping/repel duration was 14s/1s. At this pumping condition, 
60% of bound His-GFP was released, which was neither too high that the pore will be 
open nor too low that the insufficient release causes low efficiency. Triple experiments 
was carried out in this pumping condition with an average 3.1×10
-6
cm
2 
s
-1
 V
-1 
His-GFP 
effective mobility and 8.3 separation factor. Increasing the repel duration to 2s didn’t 
increase the separation factor (Table 3.1) due to the already rapidly repelled imidazole 
within 1s. 
     To further explore optimal pulse pumping conditions, different concentration bulk 
imidazole was also studied under the condition of releasing 60% of bound His-GFP. 7s/1s 
pumping/repel duration with 20 mM bulk imidazole (this will give about 108 mM 
imidazole concentration at the electrode entrance) concentration gave mild separation 
selectivity (5.3) and high mobility (5.8×10
-6 
cm
2 
s
-1
 V
-1
). This is probably because at 20 
mM bulk imidazole concentration, His-GFP can’t be bound to the membrane surface very 
efficiently, resulting inefficient blocking and releasing. Further increasing the bulk 
imidazole concentration to 30 mM will leads wide open pore and almost no selectivity 
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due to high imdazole competing with His-GFP at the electrode entrance. With 5 mM bulk 
imidazole concentration (this will give about 27 mM imidazole concentration at the 
electrode entrance), only 50% of bound His-GFP can be released from the electrode 
surface even after 20 s. A low GFP effective mobility (2.1×10
-6 
cm
2 
s
-1
 V
-1
) was seen 
when the pumping/repel duration was 23 s/1 s in 5 mM bulk imidazole concentration due 
to long releasing duration. 10 mM bulk imidazole concentration with 14s/1s 
pumping/repel conditions seems to be the best pumping conditions since both high 
separation factor and high His-GFP effective mobility can be obtained.  
     Protein binding, releasing and subsequently pumping through the membrane was also 
studied using numerical approach. His-GFP concentration during the protein binding 
cycle is calculated by Equation (5) 
                                                                             
                                                                                                               [5] 
where    is the protein diffusion coefficient. As shown in Figure 3.10, during the binding 
cycle, protein diffused from the bulk solution and was specifically captured by the Ni-
NTA chemistry at the membrane electrode/surface. His-GFP concentration at the 
electrode surface unit was set be to 0 μg/ml since the His-GFP was captured and 
immobilized on the electrode surface. During the release cycle, imidazole from the 
permeate sides will be pumped to the feed entrance to release the bound His-GFP. The 
imidazole will reach steady-state high concentration in 3s, after which bound His-GFP 
will be first released at high release rate during for 2s and low release rate for the rest 9s. 
Specially, 46% of the absorbed His-GFP (0.0019 μg) was quickly released in 2s with 
release rate R1=0.000437 μg/s and 12% of the absorbed His-GFP was slowly released in 
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9s with release rate R1 = 2.5×10
-5
 μg /s. His-GFP concentration during the protein 
releasing cycle is calculated by Equation (6) 
                                                                      
                                                                             [6] 
where    is the added protein concentration due to the protein releasing per unit time and 
   is protein mobility within the membrane.    can be calculated by Equation (7) 
                                                                                                       [7] 
Where S is membrane area and R is protein release rate. Figure 11 shows His-GFP 
pumping concentration profile during the 14s pumping cycle with 10Mm bulk imidazole 
concentration. 
Figure 3.12 shows His-GFP concentration profile at the end of pumping/releasing cycle 
as a function of different pumping cycles. His-GFP is continuously pumped from the feed 
side to the permeate side as the pulse pumping cycle repeat. Although during the repel 
cycle, His-GFP within the pore is moving backward to the feed side, however, this 
moving distance (1s repel with 8.3 V/cm electric field) is smaller compared to pumping 
distance (14s forward pumping with 50 V/cm electric field).  
    In an effort to demonstrate the ability to purify recombinant protein directly from cell 
lysate, we tried to purify the recently reported His6-OleD Loki variant directly from E. 
coli. crude lysate. His6-OleD Loki variant [ 104 , 105 , 106 , 107 ] can use aromatic 
glycosides as efficient donors in glycosyltransferase (GTs)-catalyzed reactions for both 
sugar nucleotide formation (i.e., the ‘reverse’ of a conventional GT-catalyzed reaction) 
and subsequent sugar nucleotide-mediated glycoside formation wherein the use of 2-
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chloro-4-nitrophenyl glycoside donors also offered a convenient colorimetric screen to 
enable the directed evolution of enhanced GTs with broad substrate permissivity. E. coli. 
crude lysate was directly used as feed solution with 14s/1s pumping/repel duration and 10 
mM imidazole in the permeate side. The final protein purity in the permeate side was 
determined via SDS-PAGE (Figure 3.13), which revealed more purified His6-OleD Loki 
variant compared to crude lysate. In order to test the His6-OleD Loki variant activity after 
pulse pumping purification, the enzyme specific activity was tested and compared to pure 
enzyme as shown in Figure 3.14. The His6-OleD Loki variant after pulse pumping 
purification still keeps its enzymatic activity comparable to purified enzyme.  
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3.4 Conclusion 
 
    In conclusion, numerical simulation of the pulse pumping cycles coupled with His-
GFP releasing kinetic was used to further optimize pulse pumping technology, enabling 
mimic biological membranes for efficient protein separation. His-tagged proteins bound 
to the pore entrance block other proteins in a sequential/hopping manner, allowing 
selective transport. Pulsed electrophoresis binding/release/pumping cycle allows for a 
continuous protein separation process with low cost and high productivity. This pulse 
pumping process can successfully purify His6-OleD Loki variant directly from crude E. 
coli extracts expression broth, simplifying the separation process as well as reducing 
biopharmaceutical production costs. More importantly, His6-OleD Loki was still active 
after purification confirmed by enzymatic reactions. 
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Table 3.1 Pulse pumping experiments summary 
 
 
Pumping 
condition 
10 mM 
imidazole; 
14s/1s 
pumping/re
pel  
 
10 mM  
imidazole; 
14s/1s 
pumping/rep
el  
 
10 mM  
imidazole; 
14s/1s 
pumping/re
pel  
 
10 mM  
imidazole; 
8s/1s 
pumping/rep
el  
 
10 mM  
imidazole; 
23s/1s 
pumping/re
pel  
 
10 mM  
imidazole; 
14s/2s 
pumping/re
pel  
 
20 mM  
imidazole; 
7s/1s 
pumping/re
pel  
 
30 mM  
imidazole; 
4s/1s 
pumping/re
pel  
 
5 mM  
imidazole; 
23/1s 
pumping/re
pel  
 
BSA effective 
mobility  
[10-6cm2 s-1 V-1], 
ub 
 
 
0.32 
 
 
0.5 
 
 
0.32 
 
 
0.16 
 
 
0.59 
 
 
0.52 
 
 
1.1 
 
 
2.87 
 
 
0.28 
His-GFP 
effective mobility  
[10-6cm2 s-1 V-1], 
ug 
 
 
3.1 
 
 
3.53 
 
 
2.6 
 
 
1.69 
 
 
1.82 
 
 
3.7 
 
 
5.8 
 
 
5.69 
 
 
2.1 
 
Selectivity, 
S=ug/ub 
 
 
9.7 
 
 
7.1 
 
 
8.1 
 
 
10.6 
 
 
3.1 
 
 
7.1 
 
 
5.3 
 
 
2.0 
 
 
7.5 
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 Figure 3.1 Schematic of AAO membrane blocked by his-tagged GFP pore and protein 
size drawn to appropriate scale 
  
a b
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Figure 3.2 Schematic of two-step pulse pumping processes 
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Figure 3.3 Glass surface silanization and functionalization of Nα,Nα-
Bis(carboxymethyl)-L-lysine hydrate 
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Figure 3.4 His-GFP releasing kinetic by different concentration of imidazole on the Ni-
NTA-Glass surface 
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Figure 3.5 His-GFP releasing rate by different concentration imidazole 
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Figure 3.6 Imidazole accumulation during the protein release cycle 
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Figure 3.7 Imidazole repel during the protein binding cycle; the boundary condition here 
is constant 10 mM imidazole concentration in the permeate solution. 
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Figure 3.8 Steady state imidazole concentration at different location after 1s imidazole 
repel cycle; the imidazole concentration at the pore entrance is lower than the bulk 
imidazole concentration after 1s repel.  
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Figure 3.9 Steady state imidazole concentration at different location during the imidazole 
accumulation/pumping cycle 
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Figure 3.10 His-GFP binding concentration during the 1s binding cycle; His-GFP 
diffuses into the electrode surface and was actively captured by the NTA-Ni surface 
during the binding cycle 
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Figure 3.11 His-GFP pumping concentration profile during the 14s protein 
releasing/pumping cycle with 10Mm bulk imidazole concentration  
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Figure 3.12 His-GFP concentration profile at the end of pumping/releasing cycle as a 
function of total cycle number 
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Figure 3.13 Reprehensive SDS-PAGE of OleD Loki variant purified using pulse pumping 
process directly from crude cell broth; Lanes: 1) 6 µg Crude lysate; 2) 6 µg His6-OleD 
Loki variant purified using pulse pumping process; and 3) 6 µg pure His6-OleD Loki 
variant; M) standard molecular weight markers 
  
1      2     3     M
His6-OleD Loki variant 
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Figure 3.14 Specific activity of enzyme purified using the pulse pumping system 
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Figure 3.15 Schematic of Electrophoretic pumping cell 
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Figure 3.16 Imidazole repel during the protein binding cycle; the boundary condition here 
is constant 30 mM imidazole concentration at distance0.012cm. . 
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Chapter 4 : A functionalized anodic aluminum oxide membrane-electrode system 
for enzyme immobilization 
 
 
This chapter is based on the manuscript submitted to ACS NANO: Zhiqiang Chen, 
Jianjun Zhang, Shanteri Singh, Pauline Peltier-Pain, Jon S. Thorson, Bruce. J. Hinds. ‘A 
functionalized anodic aluminum oxide membrane-electrode system for enzyme 
immobilization’, in minor revision 
 
4.1. Introduction 
 
Enzymes are biocatalysts capable of accelerating a range of chemical transformations 
relevant to materials production, pharmaceutical development and renewable energy and 
often present an attractive ‘green’ alternative to conventional synthetic strategies [108]. 
In their natural cellular/tissue environment, enzymes often assemble and/or co-localize to 
form multi-enzyme complexes or serial networks to expedite multi-step processes in part 
via minimization of substrate/product loss via diffusion [109, 110, 111, 112] and/or to 
maintain exquisite control of highly reactive intermediate species[ 113 , 114 , 115 ]. 
Additionally, the reliance upon sequential multi-enzyme processes and/or enzyme 
complexes enables metabolic control of an overall process via focused allosteric and/or 
competitive regulation of key gate-keeper enzymes within the process by 
substrate/product/cofactor concentrations [ 116 ]. Inspired, in part, by nature’s logic, 
enzyme immobilization platforms offer the potential to mimic natural multi-enzymes 
systems [117, 118, 119, 120, 121], particularly in systems where convective flow can be 
used to efficiently direct products and intermediates in sequential manner rather than 
depending upon Fickian diffusion.  
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A variety of immobilization formats for multi-enzyme processes have been developed. 
For example, simple nitrilotriacetate immobilization of His6-tagged enzymes, as 
exemplified by the ‘superbead’ approach reported by Wang and coworkers, offered 
improvements in enzyme stability and product isolation in the context of multi-enzyme 
sugar nucleotide synthesis and utilization processes[122,123]. However, such random 
immobilization strategies lack systematic control and rely on stochastic transport within 
the dense surface layer that is mechanistically analogous to homogenous solution. 
Kunitake and coworkers [124] constructed alternating layers of glucose oxidase and 
peroxidase with layer-by-layer film adsorption on a quartz slide and subsequently 
demonstrated sequential activity. Though discrete enzymatic reactions were spatially 
separated into layers in this example, the system lacked convective flow for directing the 
overall sequence of reactions. Bhattacharyya and coworkers recently developed reactive 
stacked membranes with a top membrane containing immobilized glucose oxidase and 
bottom membrane containing ferrihydrite/iron oxide nanoparticles for the degradation of 
toxic organic in water [ 125 ]. This membrane system has the advantage of using 
convective flow to direct the potentially damaging peroxide produced at the enzyme 
away to the Fe catalyst activation sites in the lower membrane layer. Building from these 
examples, an idealized structure is anticipated to derive from membrane pore bearing 
immobilized enzymes in a sequential order at nm-scale proximity. In this context, porous 
aluminum oxide (AAO) membranes offer an attractive platform due to its high pore 
density, uniform pore size and good resistance to non-specific protein adsorption [126, 
127, 128]. The precise placement of gold electrodes on an AAO membrane would also 
make it possible for tunable immobilization of sequential enzyme cascades. Gold plating 
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has been successfully used to tune pore size and add surface chemistry on AAO 
membranes. Thus, multiple enzymes could feasibly be immobilized, in a sequential 
manner, on these two nm-scale electrodes to perform multi-step reactions at the 
membrane entrance and exit respectively to mimic natural multi-enzyme sequential 
processes. 
As a simple model to demonstrate multi-step immobilized enzyme-catalyzed catalysis 
using AAO membranes, we have selected the recently reported glycosyltransferase-
catalyzed transglycosylation process reported by Thorson and coworkers [106, 107]. This 
system is based upon the development of simple aromatic glycosides as efficient donors 
in glycosyltransferase (GTs)-catalyzed reactions for both sugar nucleotide formation (i.e., 
the ‘reverse’ of a conventional GT-catalyzed reaction) and subsequent sugar nucleotide-
mediated glycoside formation wherein the use of 2-chloro-4-nitrophenyl glycoside 
donors also offered a convenient colorimetric screen to enable the directed evolution of 
enhanced GTs with broad substrate permissivity [129].  Thus, this system offers a 
convenient model of a simple two-step enzyme catalyzed process - 2-chloro-4-
nitrophenyl glycoside-driven sugar nucleotide formation and sugar nucleotide-mediated 
glycoside formation – for immobilization studies. Herein we report the successful 
immobilization of the His6-tagged engineered glycosyltransferase OleD Loki variant on 
nm-scale electrodes at the pore entrance and exit of AAO membrane through Ni-NTA 
[130], which improves both enzyme activity and stability while eliminating unwanted 
hydrolytic side reactions known to occur at higher enzyme concentrations in the solution 
phase. In addition, discrete control of each independent step of the two-step sequential 
reaction was demonstrated via selective reagent feedstock composition exposure of the 
100 
 
top and/or bottom surface of immobilized membrane/electrode system. Finally, a 
convenient one-step immobilization and purification of N-His6-OleD Loki variant 
directly from crude E. coli extracts expression broth was demonstrated to enable rapid 
immobilized catalyzed regeneration. Cumulatively, this study highlights the utility of the 
AAO membrane/electrode system as a support architecture for controlling multi-step 
enzymatic processes.  
4.2. Experimental details  
4.2.1 Materials 
 
    AAO membranes were purchased from Whatman. Gold (I) thiosulfate was purchased 
from Alfa Aesar (Ward Hill, MA) and ascorbic acid was purchased from EM Science 
(Gibbstown, NJ). Vancomycin aglyconand 2-chloro-4-nitrophenyl glucoside were 
prepared as previously reported [107, 131]. All other chemicals were purchased from 
Sigma Aldrich (Milwaukee, WI) and all chemicals were used as received unless 
otherwise noted. Swinnex 47mm filter holders was purchased from Millipore (Billerica, 
MA).  
4.2.2 Membrane/electrode fabrication 
 
     Sputtering was performed with a Cressington Coating System (Ted-Pella) with 
calibrated quartz crystal monitor with background pressure of 0.02 mbar. No intermediate 
wetting layer (i.e., Ti/TiO2) on Al2O3 was needed for seeding the Au layer. Gold (5 nm) 
was sputtered on the both top and bottom of AAO membranes followed by electro-less 
plating. Electro-less plating was performed in 50 mM phosphate buffer, pH 7.0, 
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containing 1.6 mM sodium gold (I) thiosulfate and 2.68 mM ascorbic acid . The 
oxidization and reduction reactions were given by 
 
 
Pore size before and after electro-less plating was analyzed via scanning electron 
microscopy (SEM) using a Hitachi S-4300 scanning electron microscope. 
4.2.3 Enzyme immobilization and Regeneration 
 
     N-[Nα,Nα-Bis(carboxymethyl)-L-lysine]-12-mercaptododecanamide (NTA) self-
assembled monolayer was prepared by incubation of gold with 10 mL 1 mM NTA 
ethanol solution at 25 
o
C for 24h followed by rinsing with 10 mL ethanol for 3 min and 
drying under N2 stream. The membrane was incubated with 10 mL 0.5M NiCl2 aqueous 
solution for 24 h at 25 
o
C followed by rinsing with 10 mL Milli-Q water for 3 min and 
dried under N2 stream. The production and purification of OleD Loki [129] and GtfE [132] 
followed previously reported methods. One side or both sides of the membranes were 
incubated with an excess of purified enzyme in 10 mL 50 mM Tris-HCl buffer, pH 8.5, 
for 24 h at 4 
O
C and washed with an equal volume of buffer for three times to remove 
unbound protein prior to use..Immobilized protein was released by 500 mM imidazole 
(10 mL, 50 mM Tris-HCl buffer, pH 8.5) followed by filtering to remove imidazole. The 
amount of released protein was determined via standard Bradford assay. The OleD Loki-
loaded membrane can be regenerated by simply soaking in 0.5 M EDTA (10 mL, 50 mM 
Tris-HCl buffer, pH 8.5), followed by NiCl2 reattached as described before. 
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4.2.4 Protein capture from E. coli lysates  
 
    Following standard protocol [129], cell pellets from standard heterologous 
overproduction of OleD Loki in E. coli were collected by centrifugation (6,000 xg at 4 °C 
for 20 min), resuspended in 2.5 mL of chilled lysis buffer (20 mM phosphate buffer, pH 
7.4, 0.5 M NaCl, 10 mM imidazole), and lysed by sonication (5 pulses of 1 minute each) 
in an ice bath. Cell debris was removed by centrifugation (10,000 g at 4 °C for 20 min) 
and NTA-Ni modified membranes were then incubated in the resulting crude extracts (10 
mL) for 24 h at 4 
O
C and the membranes subsequently washed with 5 mL50 mM Tris-
HCl buffer, pH 8.5 for three times to remove unbound protein. 
4.2.5 HPLC method 
 
HPLC was conducted with an Agilent 1260 system equipped with a DAD detector 
with a 250 mm x 4.6 mm Gemini-NX 5μ C18 column (Phenomenex, Torrance, CA, 
USA) and using a linear gradient of 1% B to 71% B over 30 min, 71% B for 5 min, 71% 
B to 1% B over 1 min, 1% B for 4 min (Solvent A = 50 mM PO4
2-
, 5 mM 
tetrabutylammonium bisulfate, 2% acetonitrile [pH adjusted to 6.0 with KOH]; Solvent B 
= acetonitrile; flow rate = 1 mL min
-1
; A254 nm;). Regardless of method, HPLC peak 
areas were integrated with an Agilent (Santa Clara, CA) 1260 workstation and the percent 
conversion calculated based upon peak area of the products and unreacted starting 
materials. 
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4.3 Results and Discussion 
 
The primary membrane design challenge is to localize enzyme functionality at pore 
entrances and exits to enable directional flow of substrates/products over the enzyme 
active sites in an efficient manner. Commercially available 20 nm nominal diameter AAO 
membranes are asymmetric with a thin porous layer at the top with a diameter of 27 nm 
and a bulk pore structure mainly comprised of 200 nm diameter straight channel 
monoliths. The depth that gold sputtering can reach within the top pore neck is around 20 
nm and gold electro-less plating occurs only on that deposited gold seed layer. The pore 
diameter of AAO membranes can be controlled by changing electro-less plating time as 
shown in Figure 4.1. Fifty minutes of electro-less plating time gave the desired average 
pore diameter of 10 nm match the GT of dimer length of 9.2 nm [133]. With this 
geometry GT1 (the first GT as shown in Figure 4.3) , on the 10 nm pore entrance will 
block the pore, thus excess solution GT1 can’t pass through the pore to the other side of 
AAO membrane after binding. This allows a second distinct enzyme, GT2, to be 
immobilized on the 200 nm pore side of AAO membrane to enable a directional 
sequential series of reactions. The process for N-His6-OleD immobilization on a gold 
monolayer coating based upon Bradford assay to afford a surface ‘concentration’ of 3 
g/mL immobilized enzyme within the 9.8×10
-6
 mL electrode volume .  
To demonstrate the immobilized activity of the enzyme on the membrane system we 
first compared GT-catalyzed UDP-Glc production (Figure 4.3, Reaction 1) in a standard 
solution-phase reaction to that of the membrane-supported format. The solution-phase 
reaction contained 2.6 mM glycoside donor, 1 mM UDP, 100 µg/mL OleD Loki in a total 
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volume of 200 µL l Tris-HCl (50 mM, pH 8.5) and was incubated at 25 °C for 12 h. The 
much higher than standard (typically 0.5-
in this solution-phase comparator reaction were utilized to better reflect the high local 
concentration of immobilized system (estimated as 3g/ml as previously described). The 
corresponding immobilized reaction utilized an identical reagent/reaction mixture 
(lacking enzyme) pumped through the OleD Loki loaded membrane at 1 mL/h over 4 h at 
25 °C. UDP-Glc production in the solution-phase reaction and the collected eluent from 
the solid-phase reaction was determined by HPLC (Supplementary Methods). As controls, 
identical reactions wherein OleD Loki was replaced by N-His6-tagged CalC (an enediyne 
self-resistance protein devoid of GT activity) [134, 135] were utilized to distinguish any 
potential non-enzymatic contributions to UDP-Glc production.  
Figure 4.4 highlights the outcome of this initial reaction 1 comparison and reveals a 
total 40% yield of UDP-Glc in the membrane-bound enzyme format compared to 12% in 
the solution phase and no reaction in the comparator CalC-based negative controls. 
Interestingly, significant amounts of PNP-Glc were still present in the membrane-bound 
eluent suggesting the 1 mL/h flow rate to be too fast for optimal residence time. In 
contrast, PNP-Glc was exhausted in the solution-phase reaction and corresponding low 
UDP-Glc yield was attributed to undesired PNP-Glc and UDP-Glc hydrolysis that 
unexpectedly occurred at high enzyme concentrations and extended reactions times 
(Figures 4.11 and 4.12). While a reduction of enzyme concentration and shorter reaction 
times in the solution phase format can circumvent this unwanted effect, the immobilized 
format offers the opportunity to fine-tune residence time via adjusting the flow rate to 
afford optimal UDP-Glc production in reaction 1 at high concentrations without allowing 
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the subsequent hydrolysis reaction. Within this context, the substrate residence time can 
be calculated based upon [(pore area x electrode thickness)/volume flow rate]. Thus we 
expect to achieve the best reaction yields via matching an optimal flow rate with an 
enzyme’s specific kinetics where slower enzymes might require an additional increase in 
path length. 
For the current model system, the kinetics of the solid-phase system can be estimated 
based upon enzyme loading per surface area (i.e., concentration) and flow rates. 
Specifically, the loading of OleD Loki on the nm-
local concentration of about 3 g/mL based on the pore volume of the solution adjacent to 
the 20-nm thick gold electrode. Using the average turnover number of OleD Loki (10 
min
-1
)129, the theoretical calculated UDP-Glc yield vs. flow rate (Figure 4.5) predicts 0.4 
mL/h as the optimal flow rate for continuous UDP-Glc production. Consistent with this 
model, Figure 4.5 illustrates the impact of flow rate upon UDP-Glc formation with a 
maximum yield observed experimentally at a flow rate of 0.5 mL/h. This is also 
consistent with a model wherein unwanted hydrolysis, which occurs under very high 
enzyme concentrations in the solution-phase over extended periods, does not significantly 
impact upon product formation under optimal solid-phase conditions. Specifically, nearly 
quantitative UDP glycosylation (98%, square dot shown in Figure 4.5) was observed 
experimentally at a flow rate 0.5 mL/h, illustrating the potential of the immobilized 
system to reduce unwanted side reactions and thereby optimize product output.  
Continuous production is another important merit of an immobilized platform.  UDP 
glycosylation reaction was continuously carried out at pumping rate 0.4ml/h with 
2.56Mm PNP-Glu and 1Mm UDP using the immobilized enzyme system as shown in 
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Figure 4.6.  Low UDP glycosylation yield is observed Day 1 due to dead-volume at the 
filter holder. The glycosylation yield reaches highest point at Day 3 and then decreases a 
little bit. The enzyme reserves very strong activity (almost no decrease) even after 5 day, 
which is good for long-term enzyme uses and scale-up.  Based on 0.4mL/h continuously 
pumping for 120 h and average 95.72% glycosylation yield, the total production of UDP-
Glc over the 30 µg Loki immobilized enzyme system is 4.6×10-5 mol UDP-Glc. This is 
compared to 0.2 mL of the homogeneous solution protocol with 20 µg of Loki for a total 
of 2.4x10-8 mol. The membrane flow reactor gave a 1917 fold improvement in enzyme 
utilization based on 120 h reaction. In fact, the membrane is still very active (as shown in 
figure 1) and can process much more reagents. 
Two-step sequential reactions on the membrane immobilized enzymes system were 
then carried out to mimic multi-enzyme processes, and compare their performance to 
solution-based single-glycosyltransferase coupled reactions. We selected two model GTs 
(GtfE and OleD Loki) that catalyze glucosyltransfer from UDP-Glc to model acceptors 
(vancomycin aglycon and 4-methylumbelliferone, respectively) with differing 
proficiencies. Specifically, the turnover rates for GtfE [132] and Loki [129] are 0.005 and 
10 min
-1
. For the sequential reaction platform, the reaction sequence was physically 
separated into two discrete steps with the first (UDP-Glc formation – reaction 1) 
occurring on the top face of the membrane (entry) and the second (aglycon glucosylation 
– reaction 2) on the bottom face (exit) To afford this physical separation of reactions, the 
required reagents for reaction 2 were introduced by cross-flow to the bottom surface as 
illustrated in Figure 4.7. This format allows for sequential transfer of intermediates by 
having separate reagents flowing through the top and supplied orthogonally to the bottom 
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of the membrane. Thus, for the kinetically matched pairing where both GT1 and GT2 
(Figure 4.3) are OleD Loki, the UDP-Glc formed in reaction 1 enters the reaction 2 
sequence via directional flow wherein the acceptor 4-methylumbelliferone (4Me-UMB) 
is only present in the lower reaction vessel at the membrane exit.  
For this analysis, solution-phase and membrane-supported reactions were conducted in 
parallel using similar conditions to offer a potential comparison of overall utility to afford 
the desired glycosylated product. For the kinetically matched pairing where both GT1 and 
GT2 (Figure 4.3) were OleD Loki, the solution-phase reaction contained 2.56 mM PNP-
Glc, 1 mM UDP, 0.56 mM 4Me-UMB and 100 µg/mL OleD Loki variant in a total 
volume of 200 μl 50 mM Tris-HCl (pH 8.5) incubated for 12 h at 25 °C. The 
corresponding immobilized system employed the same reagents/concentrations where 
PNP-Glc and UDP were introduced from the top of the membrane using a syringe pump 
(reaction 1) while 4Me-UMB was separately fed across the bottom of the membrane in 
orthogonal cross-flow using a second syringe pump (Figure 4.10), both at a flow rate of 
0.5 mL/h. Product formation in the solution-phase reaction and the eluent from the 
bottom solid-phase reactor face were analyzed by HPLC. 
Figure 4.8 highlights the distribution of reactants/products in the lower eluent of the 
solid-phase OleD Loki-based sequential reaction series revealing a yield of the desired 
product (4Me-UMB glucoside) 71%. The corresponding solution-phase yield of 4Me-
UMB was 16% (Figure 4.13) wherein potential GT-catalyzed reaction reversibility and 
UDP-Glc hydrolysis under longer reaction times are likely major contributors to the 
reduction of the overall yield. While this supports our initial premise that the membrane 
immobilized format serves as a potential platform for mimicking Nature’s control of 
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multi-enzyme sequential reactions, one limitation derives from a need to pair the 
corresponding enzyme catalytic efficiencies with flow rates. Consistent with this, while a 
solution-phase sequential OleD/GtfE-catalyzed reaction was previously demonstrated132, 
the kinetically mismatched (10 min
-1
 vs 0.005 min
-1
) OleD Loki (top)/GtfE (bottom) pair 
failed to afford the final desired product due to an inability to reduce the flow rate to 
sufficiently compensate for the slow turnover rate of GtfE without succumbing to back 
diffusion and unwanted OleD Loki-catalyzed hydrolysis of UDP-Glc (Figure 4.18). In 
such cases, a possible solution may be to increase the active path length 
(membrane/electrode thickness) to increase residence time or increase enzyme loading of 
the slower enzyme. 
The design of the membrane platform presented suggests that, like a standard nickel 
nitrilotriacetic acid resin-based column, this membrane should be able to ‘capture’ active 
enzyme directly from crude lysates thereby circumventing the need for protein 
purification as part of membrane preparation (Figure 4.14). To assess this, membrane was 
exposed to 5 mL of crude lysate from a standard OleD Loki E. coli heterologous 
overexpression culture for 24h, subsequently washed with Tris-HCl buffer for three times 
and the purity of the captured protein upon release via treatment with 500 mM imidazole 
in Tris-HCl buffer solution was determined via SDS-PAGE, which revealed captured 
protein with a purity of ≥99% (Figure 4.15).  Importantly, the membrane loaded via the 
crude extract capture method catalyzed nearly quantitative single step UDP-glycosylation 
(98 %) and a corresponding notable two-step  4Me-UMB glycosylation yield (80 %) at 
optimal volume flow rates  (Figure 4.16 and Figure 4.17). 
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Finally, the membrane-immobilized enzyme also displayed notable stability even after 
two months of cold storage at 4℃. Specifically, the immobilized enzyme T1/2 based upon 
UDP-Glc formation was more than 55 days (Figure 4.9). In addition, the membrane 
platform is robust and could be reused multiple times via a simple regeneration process 
(removal of protein with 500 mM imidazole, rinsing with Tris-HCl buffer and subsequent 
protein reloading).  
4.4. Conclusion  
In conclusion, we have demonstrated a design for a robust sequential enzyme reaction 
system immobilized on nano-scale electrodes at the entrance and exit of AAO membranes. 
The local enzyme concentration at the nano-scale electrodes is much higher compared to 
homogenous solution and allows precise control of the enzyme residence time of 
substrates, translating to improvements in overall output via the reduction of unwanted 
side reactions (hydrolysis) and/or potential product inhibitors. Model sequential reactions 
using the same format revealed similar advantages wherein a main limitation stems from 
the need to pair enzymes of similar catalytic efficiencies with overall flow rate. In 
situations where catalytic efficiencies of catalysts dramatically differ, it is expected that 
extending the path length (i.e., surface area) for slower catalysts could enable pairing 
with faster catalytic partners. Additional advantages observed in this study include the 
ability to rapidly capture target catalysts from crude E. coli lysates and the relatively 
long-term stability of target catalysts and corresponding membrane architecture. As such, 
this membrane platform offers an opportunity to expand the study and biocatalytic utility 
of multi-enzyme cascades with directed mass transport.  
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Figure 4.1SEM images of bare AAO membrane and electro-less plated AAO membrane 
on top surface sputtered seed layer. 
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Figure 4.2 Enzyme immobilization process onto Au electrodes at AAO pore entrances. In 
the presence of excess N-His6-enzyme for 24 h (see experimental section), the 20 nm 
pore size surface is routinely coated with 30 µg g of enzyme, affording a local surface 
concentration of 3g/mL.  
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Figure 4.3 Model reactions utilized to assess the immobilized platform. Reaction 1 is a 2-
chloro-4-nitrophenyl glucoside (PNP-Glc) driven glycosyltransferase-catalyzed ‘reverse’ 
reaction to produce the desired sugar nucleotide UDP-Glc. Reaction 2 is a standard 
glycosyltransferase-catalyzed glycosylation of the model acceptor 4Me-Umb where the 
UDP-Glc from reaction 1 serves as the sugar donor in a sequential reaction. For the 
current study, reaction 1 occurs on the top face while reaction 2 occurs at the bottom face 
of the reactor membrane, respectively. 
  
  
4-methylumbelliferone
2-chloro-4-nitrophenolate 
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Figure 4.4 Representative HPLC analysis of UDP-Glc production (reaction 1) using 
solution-phase enzyme and membrane-supported enzyme. The solution-phase reaction 
contained 2.6 mM glycoside donor, 1 mM UDP, 100 µg/mL OleD Loki in a total volume 
of 200 µL l50 mM Tris-HCl, pH 8.5 and were incubated at 25 °C for 12 h. The 
immobilized reaction contained 4mL of the same reagent mix (lacking solution-phase 
OleD Loki) injected through the membrane containing a total of 30  µg  immobilized 
OleD Loki at a flow rate of 1 mL/h at 25 °C for 4h. Resulting reactions were 
subsequently analyzed by HPLC  
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Figure 4.5 Calculated (dotted line) and observed UDP-Glc production as a function of 
flow rate; for pumping rate 0.2 mL/h, 1 ml/h and 2 mL/h, the pumping time was 4h and 
for pumping rate 4 mL/h and 8 mL/h, the pumping time was 1h.  Day 1 refers to a 
complete series of runs at specified pumping rates, followed by repeating a 2
nd
 complete 
series on Day 2, to show enzyme stability.  
  
115 
 
 
Figure 4.6 Continuous UDP Glycosylation yield through membrane carrying 
immobilized OleD Loki (from crude extract capture method).The UDP glycosylation 
reaction was continuously carried out at pumping rate 0.4mL/h with 2.56 mM PNP-Glu 
and 1Mm UDP using the immobilized enzyme system.  
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Figure 4.7 The configuration for the solid-phase two-step sequential reaction process 
(Figure 3 reaction 1, top face; reaction 2, bottom face) catalyzed by AAO membrane-
immobilized OleD Loki.  
  
UDP+PNP-Glc Reaction 1
4Me-UMB
Reaction 2
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Figure 4.8 HPLC analysis of a representative immobilized sequential reaction containing 
2.56 mM PNP-Glc and 1 mM UDP in 50 mM Tris-HCl, pH 8.5 in the upper reactant 
chamber injected through the membrane carrying immobilized OleD Loki on the top and 
bottom face into a bottom reaction chamber containing 0.56 mM 4Me-UMB in same 
buffer. Flow rate for this sequential reaction was 0.5mL/h at 25 °C for 4h and the bottom 
reaction chamber contents were subsequently analyzed by HPLC. 
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Figure 4.9 Stability of immobilized enzyme stored at 4 ℃ where percent conversion is 
based upon UDP-Glc formation (reaction 1) as determined via HPLC.  
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Figure 4.10 Set-up for membrane-based sequential reactions; PNP-Glc and UDP were 
introduced from the top of the membrane using pump1 (reaction 1) and 4Me-UMB was 
separately fed across the bottom of the membrane in orthogonal cross-flow using pump 2, 
both at a flow rate of 0.5 mL/h.   
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Figure 4.11 Representative hydrolysis of UDP-Glc (reaction 1 product) by OleD Loki at 
higher concentrations of catalyst in a solution-phase reaction (reaction conditions: 0.5 
mM UDP-Glc, 100  µg /mL Loki, 100 µL Tris-HCl, pH 8.0, 25 
o
C; at the time points 
indicated, 30  µL aliquots were quenched with an equal volume of MeOH and analyzed 
via HPLC). 
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Figure 4.12 Representative hydrolysis of PNP-Glc (reaction 1 substrate) by OleD Loki at 
higher concentrations of catalyst in a solution-phase reaction (reaction conditions: 0.5 
mM UDP-Glc, 100 µg /mL Loki, 100  µL Tris-HCl, pH 8.0, 25 
o
C; at the time points 
indicated, 30 µL aliquots were quenched with an equal volume of MeOH and analyzed 
via HPLC). 
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Figure 4.13 HPLC analysis of a representative solution-phase sequential reaction 
containing 2.56 mM PNP-Glc, 100 ug/mL OleD Loki, 1 mM UDP, 0.56 mM 4Me-UMB, 
in 200 μl 50 mM Tris-HCl, pH 8.5 incubated at 25 °C for 12h. 
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Figure 4.14 Illustration of the one-step capture from an OleD Loki E. coli overproduction 
crude cell extract (see experimental section for details).  
  
cell crude broth
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Figure 4.15 Representative SDS-PAGE of OleD Loki released from AAO membrane 
after one-step capture process. Lanes: 1) pure OleD Loki; M) standard molecular weight 
markers; 2) 7 µg captured OleD Loki released from AAO membrane; and 3) 14 µg 
captured OleD Loki released from AAO membrane. Lanes 2 and 3 were purposefully 
overloaded to delineate potential impurities associated with the capture method.  
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Figure 4.16 Representative HPLC analysis of UDP-Glc production (reaction 1) using 
membrane-supported enzyme prepared via the crude extract capture method. The 
solution-phase reaction and were incubated at 25 °C for 12 h. The immobilized reaction 
contained 2.6 mM glycoside donor and 1 mM UDP in a total volume of 2 mL 50 mM 
Tris-HCl, pH 8.5 injected through the membrane containing a total of 30 µg captured 
OleD Loki at a flow rate of 0.5 mL/h at 25 °C for 4h. Resulting reactions were 
subsequently analyzed by HPLC. For comparisons, Figure 4 highlights a representative 
immobilized reaction loaded with previously purified OleD Loki and a representative 
solution-phase comparator reaction. 
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Figure 4.17 HPLC analysis of a representative immobilized sequential reaction 
containing 2.56 mM PNP-Glc and 1 mM UDP in 50 mM Tris-HCl, pH 8.5 in the upper 
reactant chamber injected through the membrane carrying immobilized OleD Loki (from 
crude extract capture method) on the top and bottom face into a bottom reaction chamber 
containing 0.56 mM 4Me-UMB in same buffer. Flow rate for this sequential reaction was 
0.5mL/h at 25 °C for 4h and the bottom reaction chamber contents were subsequently 
analyzed by HPLC.  
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Figure 4.18 Scheme for an OleD Loki/GtfE sequential coupled reaction for glucosylation 
of the vancomycin aglycon. (Reprinted from Ref [132]) 
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Chapter 5 : Flow-through Electroporation of HL-60 White Blood Cell Suspensions 
using Nanoporous Membrane Electrodes 
 
 
5.1 Introduction 
 
       The genetic modification of free-flowing white blood cells is highly attractive for 
therapy.  The white blood cells are complex organisms that are able to destroy targeted 
cells through the expression of specific anti-body receptors on its cell wall.  Another 
approach to utilizing white blood cells is to have these genetically modified cells 
continually express needed biomolecules to be distributed through the cardiovascular 
system.  In a recent ground-breaking study, white blood t-cells were genetically modified 
with exogenous DNA (lentivirus vector) and ‘programmed’ to destroy cancer cells. This 
method was shown to be an effective treatment for a patient with leukemia [136]. 
However due to the use of viral vector, immune response and hypogammaglobulinemia 
were detected.  Moreover, it is a delicate balance to modify a t-cell to attack cancer cells 
and not healthy cells, thus there is a significant inherent risk to permanently modifying all 
t-cells in a large patient population through a virus vector.  For safe treatment, one would 
be able to modify a controlled number of cells with known lifetime, which in-principle 
can be achieved with a flow electroporation system. 
       Recent developments in micro-fabrication technology facilitated the development of 
microfluidic electroporation to address the disadvantages of traditional electroporation 
approaches [137, 138, 139, 140]. Here we present a low cost, high cell viability and high-
throughput electroporation method based on a novel, microfluidics-based nanoporous 
membrane/electrodes approach. Gold electrodes were introduced on the entrance and exit 
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of an Anodic Aluminum Oxide (AAO) membrane through sputtering and gold electro-
less plating. Voltages as low as 1V applied across the 60 µm membrane thickness 
generated sufficient electric field for cellular electroporation at pore entrances. Standard 
photo-lithography was used to create PDMS micro-channels on the membrane/electrodes 
system with a channel height matched to Leukocyte dimensions. HL-60 cells (difficult to 
transfect cells) were continuously squeezed through the micro-channel in contact with the 
nanoporous electroporation electrode. Low voltage due to nm-scale concentrated electric 
fields at pore entrances in a periodic array resulted in high cell viability while maintain 
high transfection rate. Importantly, the transfection model reagent was electrophoretically 
pumped from the reservoir across the membrane/electrode system to the micro-fluidic 
channel, which reduced the reagent use by 8 fold.  
 
5.2 Experimental details  
5.2.1 Materials  
 
   All the chemicals were used as received. 200nm pore diameter Anodic aluminum oxide 
(AAO) membrane was purchased from Whatman. Gold (I) thiosulfate was purchased 
from Alfa Aesar. Ascorbic acid was purchased from EM Science. Lucifer yellow CH 
dilithium salt (LY, MW~457, 428/540 nm) and Propidium iodide (PI, MW~668, 535/617 
nm) were purchased from Sigma Aldrich. Isotonic phosphate-buffered saline was 
purchased from Mediatech. Negative photoresist SU-8 3005 was obtained from 
MicroChem. Silicon wafers was obtained from University Wafer, South Boston, MA. 
RTV615 001-KIT (Polydimethylsiloxane prepolymer) was purchased from MG 
chemicals, Toronto, Canada. Purified water was prepared using a Millipore Milli-Q water 
130 
 
purification system with 18.0 MΩ.cm resistivity.  
5.2.2 Cell culture 
 
   HL-60 cells were purchased from the American Type Culture Collection (ATCC) and 
cultured in RPMI 1640 (Invitrogen) media supplemented with 10% Fetal bovine serum 
(FBS) and 1% penicillin-streptomycin-L-glutamate (PSG, Sigma Aldrich) under standard 
incubator conditions (i.e., humidified, 5% CO2/95% air environment maintained at 37
o
C). 
The cells were fed and split every 2-3days to maintain the cell density within cultures 
between 2.5×10
5
 and 1.0x10
6
 cells /ml.  
5.2.3 Device fabrication  
 
Nanoporous membrane electrodes were synthesized by gold plating on commercial 
Anopore aluminum oxide (AAO) membranes. Gold sputtering was first performed to 
create gold seed for the gold electro-less plating. Sputtering was performed with a 
Cressington Coating System (Ted-Pella) with calibrated quartz crystal monitor with 
background pressure of 0.02 mbar at 100W power supply. No intermediate wetting layer 
(i.e. Ti/TiO2) on Al2O3 was needed for seeding the Au layer. A thin (5 nm) layer of gold 
was sputtered on both the top and bottom of the AAO membranes followed by electroless 
plating. Electroless-plating was performed with membrane in 50 mM pH 7.0 phosphate 
buffer containing 1.6 mM sodium gold (I) thiosulfate and 2.68 mM ascorbic acid.  
     The micro-channel master was fabricated following standard soft lithography 
procedures
141
. First, a photo-mask containing clear 7mm×4mm rectangles was designed 
using Adobe illustrator and printed on high resolution transparency film. Negative 
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photoresist SU-8 3005 was pippeted on to a 4cm×4cm silicon wafer and spun coat at 
1000 rpm to obtain 10µm thickness photoresist that acts as the channel height during 
PDMS mold transfer. The wafer was then baked at 95 °C for 3 min and exposed to UV 
light for 12s to replicate the pattern into the photoresist. The wafer was then baked at 
95 °C for an additional 80s before incubation in SU-8 developer. Finally, the wafer was 
baked to hardness at 160 °C for 2 min. This master was used to generate 7mm length (L), 
4mm width (W) and 10µm tall (H) channel for this study.  Polydimethylsiloxane (PDMS) 
prepolymer resin and hardener was mixed with a mass ratio of 10:1. The mixture was 
stirred with a clean glass stirring rod until it became milky in appearance. The mixture 
was then evacuated for 2 h to remove any air bubbles in the PDMS, poured onto the 
master, and baked at 80 °C for 1 h. The cured PDMS replica was then peeled off and 
punched to produce inlet and outlet ports. TYGON® Polyvinyl chloride (PVC) tubing 
(Amazon) with 0.02 inch inner diameter and 0.06 inch outer diameter was inserted into 
the inlet an outlet ports respectively.  
      Finally, gold electrodes/membrane was bonded to the PDMS according to procedures 
reported by Sunkara and coworkers [142]. The gold electrode was first cleaned with 
piranha solution (The ratio of concentrated H2SO4 and H2O2 is 5:1) before treatment with 
oxygen plasma for 2 min. The oxygen plasma treated electrodes were then incubated in a 
10% (volume) aminopropyltriethoxy silane (APTES) aqueous solution for 20 min. The 
electrode was subsequently washed with DI water and dried under Nitrogen gas for 1min. 
PDMS mold was also treated with oxygen plasma for 2 min. Finally the activated gold 
electrode and PDMS device were then placed in conformal contact at room temperature 
for 12h to form bonding sufficient to prevent leakage during flow experiments. 
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5.2.4 Electric field model 
 
COMSOL 4.3 (COMSOL, Inc, Burlington, MA) was used to model the electric field of 
the device. The electric field across the membrane/electrode system was determined by 
solving the Laplace equation [143] 
            
 
Where   and   stand for the electric conductivity and electric potential, respectively. A 
stationary 2D “Electric Current” mode under AC/DC model was created for the 
simulation. The model geometry is described as 0.2um pores separated by 0.5um Al2O3 
wall with a thickness of 60um. Phosphate-buffered saline is filled within the geometry 
pore. The electric conductivity of the phosphate-buffered saline is 0.127 S/m [144]. The 
electric conductivity of Al2O3 is 10
-5
 S/m. The boundary conditions were a constant 1V 
potential on the top of Al2O3 walls and 0V potential on the bottom of Al2O3 walls. The 
geometry was built with fine element mesh and computed. (see the supporting 
information for detail COMSOL instructions) 
COMSOL Model instructions: 
 
Model Wizard 
1. Double click the COMSOL icon on the desktop to create a new model 
2. In the select space dimension window, select 2D. 
3. In Select Physics, select AC/DC > Electric Currents (ec). Click Add. Click next 
Study to continue. 
4. Click Stationary under Preset Studies. Click done once you have finished. 
Geometry 
1. Draw a rectangle with 6um width and 60 um Height at (0um, 0um) position 
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2. Draw eleven rectangles with 0.2 µm width and 60 µm Height at positions (0µm, 
0µm), (0.5µm, 0µm), (1µm, 0µm), (1.5µm, 0µm), (2µm, 0µm), (2.5µm, 0µm), (-
0.5µm, 0µm), (-1µm, 0µm), (-1.5µm, 0µm), (-2µm, 0µm) and (-2.5µm, 0µm) 
Materials 
1. Open Material Browser>Built in>Water, liquid; Click select and rename as 
Phosphate buffer; in the materials contents column, change the electrical 
conductivity value to 0.127 S/m. 
2. Select Phosphate buffer, in the Geometric Entity Selection area, select the 
following domains: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 
3. Open Material Browser> Built in>Alumina; Click select; in the materials contents 
column, change the electrical conductivity value to 10e-5 S/m. 
4. Select Alumina, in the Geometric Entity Selection area, select the following 
domains: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23 
Domain Physics and Boundary Conditions 
1. In the Model Builder, right-click Electric Currents (ec) and add electric potential 
2. Select initial values under the electric currents; Put 0V as the electric potential for 
all domains’ initial value. 
3. Select Electric potential 1; manually choose the following boundaries: 3, 9, 15, 21, 
27, 33, 39, 45, 51, 57, 63, 69; In the Electric potential column, put 1V as the 
potential for the selected boundaries. 
4. Select Electric potential 2; manually choose the following boundaries: 2, 8, 14, 20, 
26, 32, 38, 44, 50, 56, 62, 68; In the Electric potential column, put 0V as the 
potential for the selected boundaries. 
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Mesh 
1. In the Model Builder, under Component 1 click Mesh 1. In the Mesh settings 
window, under Mesh Settings, select Fine from the Element size list. 
2. Click the Build All button on the Mesh settings window toolbar. 
Study 
1. Right-click Study 1 and select Compute (or press F8) 
Displaying results 
1. In the Model Builder, right click Result and select 2D plot group 
2. Right click 2D plot Group and select surface 
3. Select surface and in the expression column put “ec.normE” with unit “V/cm” 
4. Plot the result  
5.2.5 Static electroporation without PMDS channel 
 
     Suspended cell electroporation without vacuum filtration: 1.4 mL of solution of HL60 
cells in RPMI media at a concentration of 1.3 million cells per milliliter was suspended 
on top of the gold-plated AAO membrane tissue culture insert (Nunc Anopore® 
Membranes).The working electrode was connected to the top bottom electrode/membrane 
surface, while the counter/reference electrodes to the bottom electrode/membrane surface. 
Cells were electroporated at 1V with 20 ms pulses of electricity spaced 1 s apart. A total 
of ten pulses of electricity were applied. The insert was then allowed to sit in the holding 
for 35 minutes. The cell solution was then centrifuged and the supernatant was removed. 
Fresh cell media was added, and the process was repeated twice more, to remove 
extracellular LY from solution before cell visualization under the fluorescent microscope 
as described before.  
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       Cell electroporation with vacuum filtration: The cell insert was sealed above a 
vacuum filtration flask for 3 hours to allow the cells to come in direct contact with the 
AAO membrane before performing the electroporation.  
5.2.6 Flow-through electroporation 
 
      A syringe pump (The New Era Pump Systems, Inc) was connected to the inlet end of 
the device through clear PVC tubing. A potentiostat (EA164 QuadStat, eDAQ Pty Ltd) 
controlled by an e-corder 410 (eDAQ Pty Ltd) with ChartTM software was used as a 
pulse generator. The working electrode was connected to the top electrode/membrane 
surface, while the counter/reference electrodes to the bottom electrode/membrane surface, 
as shown in Fig.4.  The channel was flushed with phosphate-buffered saline for 3min at 
1ml/min to remove impurities within the channel.  
Prior to electroporation, HL-60 cells were centrifuged at 200g for 5 min and re-suspended 
in phosphate-buffered saline containing 1mg/ml Lucifer Yellow to a final concentration 
of 1×10
6
 cells /ml. The cells/Lucifer Yellow mixture was subsequently flowed through 
the device for electroporation while a pulse voltage (20ms per pulse in 1 sec intervals) 
across the membrane was applied.  Cells were collected from the outlet and incubated in 
room temperature for 35mins. The cells were then ringed three times with phosphate-
buffered saline prior to transfection and viability assay.   
In a separate experiment to show the efficient electrophoretic pumping of Lucifer Yellow 
reagent across the membrane, only cells in PBS buffer were flowed through the channel 
while 1mg/ml Lucifer Yellow was placed beneath the electrode/membrane device during 
the electroporation process.  
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5.2.7 Transfection and viability assays 
 
     A final 1ug/ml propidium iodide (PI) was added to the washed cells for cell viability 
assay. 
Both phase contrast and fluorescent images of cells were captured using an Eclipse 
LV100D-U fluorescence microscope (Nikon) with NIS-Elements BR 3.0 software 
(Nikon). An LSR II flow cytometer (Becton -Dickinson) with Becton - Dickinson 
interfaced to FACsDiva computer software was used to quantify dye uptake by 
electroporated cells and cell viability. At least 10,000 HL-60 cells were acquired at a rate 
up to 1000 cells/s for each sample. A 488-nm line of an argon laser (Innova, Coherent, 
Palo Alto, CA) was used to excite LY in transfected cells and PI in dead cells. The two 
filters used were Percp-Cy5.5 filter (695/40) for PI emission detection and FITC (530/30) 
for LY emission detection. Spectral compensation was conducted to account for the 
overlap in emission between propidium iodide into the Lucifer yellow.   
5.3 Results and Discussion 
 
     To achieve cellular electroporation at low voltages, micron-scale distance between the 
two electrodes is required. This can be easily achieved with electrodes on each side of 
commercially available AAO membranes that are 60µm thick.   Gold sputtering 
deposition on both the top and bottom of AAO membrane served as catalytic seeds for 
the subsequent electro-less plating of thicker gold layers to reduce pore size and overall 
porosity. Figure 5.1 shows the typical SEM images of the bare membrane and the 
membrane after sputtering and electro-less plating fabrication steps.  
      Figure 5.2 shows the simulated electric field distribution at top entrance of 
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membrane/electrodes using COMSOL modeling software. The modeling of electric field 
(EF) concentration at pore entrance shows a “butterfly EF distribution shape” with EF as 
high as 540V/cm at the pore edges and EF as low as 100 V/cm in the pore center. The 
bulk pore EF is near 167 V/cm, which is simply approximated by applied voltage divided 
by thickness (1V/60µm).  Table 1 summarizes the voltages applied in the experiments 
and the resulting field intensities in the bulk pore and at pore entrance. The maximum EF 
field at the pore entrance is proportion (3.2 times) the bulk applied field.  In the common 
electroporation process, the whole cell is placed between electrodes for electroporation 
with the entire area of the plasma membrane perpendicular to desired electric field (150-
424 V/cm). This gives the fundamental reason for the difficulty of finding an appropriate 
electroporation voltage in the conventional geometry: too high a voltage and large area 
damage to the plasma membrane is not physiologically repairable thereby killing the cell, 
while at too low a voltage there is no pore formation.  Ideally one would localize strong 
electric in nm-scale areas with a regular arrayed pitch allowing for high poration that is 
repairable and inject the transfection reagent during the voltage pulse.  By injecting the 
reagent during poration, it is possible to have the cell nearly immediately repair 
electroporation damage, thereby increasing cell viability.  Our gold electrode/membranes 
system has the strongest electric field at the pore entrances which is a relatively small 
(~5%) percentage of the cell’s plasma membrane area with regular 200nm spacing.  Also 
charged transfection reagents can be electrophoretically pumped across the membrane 
into the cell.  
      To take advantage of this geometry, the cells must be in direct contact with the 
membrane/electrode surface.  Experiments with suspended cells above AAO/electrode 
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membranes failed to transfect until a filtering vacuum was applied to make cells contact 
the electrode, however this approach is not scalable to large numbers of cells (Figure 5.9 
in supporting information).  Due to the nature of the vascular system constricting to 
cellular sizes, white blood cells are robust to mechanical deformation and can be flowed 
through channels with cellular dimension to give contact with the membrane/electrode 
surface.  HL-60 cells have 10-20 µm diameters thereby requiring a channel height 10µm 
above the Au/AAO membrane surface to squeeze the cells into direct contact with the 
pore entrances.  Figure 5.4 shows the schematic setup for the flow-through 
electroporation of HL-60 cells using the PDMS channel over the electrodes/membrane 
system.   
      Fluorescence microscopy of cells flowed through the device, in Figure 5.5, 
demonstrate the successful electroporation of cells to introduce cell-impermeable Lucifer 
yellow as a transfection agent model compound.  When HL-60 cells flow through the 
micro-channel, the cell wall is forced into intimate contact with the electrode pore 
entrance and exposed to a 20 ms voltage pulse to porate the cell. In this case the Lucifer 
yellow (LY) transfection model reagent is in the bulk carrier solution and enters the cells.   
Since the living cell repairs the porated cell wall, the cell wall impermeable LY is trapped 
inside the cell allowing fluorescent microscopy imaging of transfected cell (green).  To 
image dead cells, those highly permeable walls are readily stained with propidium iodide.  
Importantly there were no imaged transfected cells and minimal dead cells in the control 
(0V) experiment showing that the act of flowing of white blood cells through the micro-
channel over the membrane does not damage/porate the cell walls. As the applied voltage 
is increased from 1 to 4V, the electric field within the electrode pore entrance is increased, 
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resulting in an increased cell transfection. This applied voltage is significantly low than 
commonly used 20-100V and prior reports (9V) with adherent cells on AAO membranes.  
Unlike traditional cuvette electroporation process, there were very few dead cells imaged 
in this process.  Fluorescent microscopy suffers from low statistical sampling, thus 
detailed cell viability and cell transfection efficiency were determined using high-
throughput and automated flow cytometry using the same fluorescent transfection marker 
(green) and dead cell marker (red).  As shown in Figure 5.6, when the voltage increased 
from 0V to 4V, the cell population exhibits a fluorescence intensity shift from live non-
transfected (zone Q3) to live transfected (zone Q1), which indicated the statistically valid 
increase of cell transfection while retaining high cell viability.  
         Traditionally, the cell transfection efficiency and cell viability are trade-off 
parameters with an inherent non-ideal maximum. At low voltage, the cell transfection 
efficiency is low and the cell viability is high because cells undergo a low level of 
reversible electroporation before the transfection reagent can enter the cell. At high 
voltage, the cell transfection efficiency is high with significant irreversible poration 
resulting in low cell viability. Our electroporation device, however, showed high cell 
viability at high transfection rates, as shown in figure 5.7.  At 1 V applied voltage the 
device showed ~30% cell transfection efficiency and >90% cell viability while at 4 V 
applied voltage device showed ~65% cell transfection efficiency with similar >90% cell 
viability. 
      There are two likely reasons to account for the high cell viability in our device. First, 
unlike traditional electroporation processes where the whole cell membrane is exposed to 
high voltage (or is it high current) electric fields, only a small part of the cell membrane 
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(~5%) is exposed to the nm-scale focused electric field at pore entrances in our device in 
a periodic array of the AAO membrane (~250nm spacing). This focused electroporation 
reduces the possibilities of irreversible electroporation and cell death. In traditional 
electroporation process, however, the whole cell was exposed to unfocused strong electric 
field, thus there is a much higher possibility of large areas irreversible electroporation.  
Second, the electric current induced joule heating in our device is much lower than the 
conventional electroporation device, where temperatures can increase as high as 10 K 
[140]. The electric current ranges from 1 uA to 8 uA when the applied 20ms pulse voltage 
at 1s interval ranges from 1 V to 4 V. The joule heating induced temperature rise can be 
calculated using the following equation: 
                                  (1) 
Where U is applied pulse voltage, I is current, t is time, c is the water specific heat 
capacity, m is the flowing water total mass and    is the rising temperature. In the worst 
case (with the flow rate of 1 mL/h, the highest voltage 4 V, and the highest current of 8 
uA), the calculated joule heating induced temperature gain is 5x10
-6
 K, thus eliminating 
that potential mechanism of cell stress.  
     Another critical merit to this device design is that the transfection reagents can be 
electrophoretically pumped from the reservoir across the membrane/electrode system into 
the cell.  This can dramatically reduce the amount of expensive-to-produce transfection 
reagents that are traditionally mixed with the flowing cell solution and need to be at 
concentrations high enough to enter the cell before the porated cell wall is repaired. Thus, 
only a small part of the reagents are transferred into the cell and the rest are not reused 
and are usually discarded. Typically, 10
9 
cells are needed for a clinical application, which 
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often would require 1 L 10
6
cells/ml mixed with 1mg/ml reagents solution. With our 
Lucifer yellow model transfection reagents the total amount needed for a single clinical 
trial would be 1000 mg. By electrophoretically injecting the transfection agent into cells 
from a reservoir located under the membrane/electrode we can greatly reduce the amount 
of expensive reagents used during the transfection process. To demonstrate this, aliquots 
(2 mL) of 1mg/ml Lucifer yellow was placed beneath the membrane/electrode system 
(Figure 5.4). The negatively charged Lucifer yellow would be electrophoretically pumped 
to the micro-channel and delivered into the cell membrane under high electric field 
generated by the pulse voltage. As shown in figure 5.8, the simultaneous electrophoresis 
pumping of Lucifer yellow and electroporation of HL-60 cells show similar cell 
transfection efficiency and viability as shown in Figure 5.6. The amount of Lucifer 
yellow being pumped across the 4mm×7mm channel during 20ms electrophoretic 
pumping can be calculated by  
                                              (2), 
where  =8×10-5 cm2/(V.s) is the Lucifer yellow electrophoretic mobility [145],  =167 
V/cm is the electric field,   =1mg/ml is the Lucifer yellow concentration, t=0.02s is the 
pumping duration, S is the channel area, and 50% is the average membrane porosity. 
Based on equation 1, the amount of Lucifer yellow pumped across the 4mm×7mm 
channel per pulse is 3.7×10
-5
 mg. To process 1000ml 10
6
cells/ml cells at pumping rate 
1ml/h, the needed electrophoretic pulse number is 3.6×10
6
, requiring 135 mg Lucifer 
yellow provided beneath the membrane system. This is 8 fold less (13.5%) than the 
amount needed when LY is simply mixed with HL-60 cell solution in a conventional flow 
electroporation approach. 
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    The last merit of the flowing electroporation system is that it can continuously 
transfect a large number of cells. Traditionally, the cells and biomolecules are mixed 
together for electroporation in a fixed-volume cuvette with two plate electrodes. Thus, 
electroporation is performed in a batch mode with a small number of cells. In our device, 
cells can be continuously flowed through 10µm height channels with the pumping rate 
controlled by the syringe pump. More importantly, our device can be easily scaled up by 
increasing the width and length of the PDMS channel and increasing the voltage pulse 
frequency. In our experiment, a single 20 ms pulse duration (  ) was chosen for the HL-
60 transfection process which was applied every second to match the cell residence time 
in the channel.  The cell residence time can be determined by the channel dimensions (H, 
L, W) and the cell solution volume flow rate (v).  
  
   
 
 (s)                                (2) 
With a flow rate 1ml/h, channel width (W) 4 mm, channel length (L) 7 mm and channel 
height (H) 10 µm, a 1s cell residence time was chosen according to equation 1 for our 
experiment.  The minimum transit time for cells to receive a single electroporation pulse 
and purge the channel is twice the time of the 20ms voltage pulse duration (  ). With 
commonly available concentration of cells ~1×10
6
 /ml, a 1L/h flow rate for one hour 
would deliver the 10
9
 cells required for clinical trials [146].  By rearranging Equation 2, 
the required planar membrane active area (A=L×W) is given by: 
         
    
 
                            (3) 
Thus using equation (3), a 3.3cm x 3.3 cm membrane with 40 ms pulse period would give 
the necessary 1 L/h flow rates for clinical use. This is an area readily achievable with 
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commercially available materials. 
 
5.4 Conclusions 
 
    A robust nanoporous membrane/gold electrodes system has demonstrated the 
continuous electroporation of HL-60 cells in a flowing white blood cell suspension 
culture. COMSOL simulation showed that low voltages (1-4 V) can generate sufficient 
electric field for electroporation at the electrode pore entrances with nm-scale focus and 
regular periodicity.  The low voltages, low joule heating and periodic poration sites allow 
for high cell viability (>90%) and 65% cell transfection efficiency. HL-60 cells (10-20 
µm diameter), a cell line recognized to be difficult to transfect, can be “forced” to interact 
with the electrode pore entrance and exposed to high electric field when passing through 
a 10 µm height micro-fluidic channel above the membrane/electrodes.  This device can 
be scaled up to increase the cell sample volume by simply varying the geometry of the 
micro-fluidic channel and/or pulse voltage frequency for faster residence time. Finally, 
we demonstrated that Lucifer yellow can be electrophoretically pumped across the 
membrane/electrodes system during the electroporation process from a reservoir located 
below the flow chamber, which greatly reduced (8 fold) the amount of expensive 
biomolecules used during the transfection process. We envision that this 
membrane/electrode system will show promise in clinical applications where low-cost, 
high cell viability and high volume transfected methods are needed without the risk of 
viral vectors.  In particular the genetic modification freely mobile white blood cells to 
either target disease cells or express needed protein/enzyme biomolecules is an important 
target platform enabled by this device system.    
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Table 5.1 The applied voltages across the device (V) and the resulted field intensities  
V(V) 0 1 2 4 
Bulk Pore Field (V/cm) 0 167 334 668 
Maximum Field (V/cm) 0 540 1080 2160 
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Figure 5.1 SEM images of cell culture side of AAO membrane. (a) Top view of bare 
membrane. (b) Cross section of bare membrane. (c) Top view of gold-coated membrane. 
(d) Cross section of gold-coated membrane.  
  
60µm distance electrode 
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Figure 5.2 COMSOL simulation of electric field (EF) distribution at the top of 
membrane/electrode system at 1V applied voltage 
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Figure 5.3 Fabrication process of PDMS-membrane/electrodes device for cellular 
electroporation 
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Figure 5.4 Schematic illustration of the setup for large-volume flowing cell transfection  
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Figure 5.5 Fluorescent image overlay after cellular electroporation using the micro-
channel device. 
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Figure 5.6 Representative two dimensions dot plot of flow cytometry data after different 
electroporation voltages.  Quandrants are live transfected cells (Q1, LTC), dead 
transfected cells (Q2, DTC), live un-transfected cells (Q3, LUC) and dead un-transfected 
cells (Q4, DUC).  
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Figure 5.7 Cell transfection efficiency (electroporated live cells/ total live cells 
  
     
   
and cell viability (live cells/total cells = (
     
           
) as a function of applied 
electroporation voltage. Data shown are the mean ± S.D. of results obtained from three 
independent transfection experiments with .flow cytometry data (total number of cells 
analyzed is 10,000 in each run) 
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Figure 5.8 Representative two dimensions dot plot of flow cytometry data for 
simultaneous electrophoresis pumping of Lucifer yellow and transfection of HL-60 cells 
at 1v applied voltage.  Quadrants 1-4 are as defined in Figure 5.6. 
  
Transfection efficiency: 35.7%±10.8%
Cell viability:94.6%±3.2%
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Figure 5.9 Optical and fluorescent images of HL-60 cells before and after electroporation 
without (A) and with (B) vacuum filtration; scale bars, 50µm. Good contact between cells 
and electrodes is necessary for efficient transfection.  
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Chapter 6 : Conclusion 
 
AAO membrane is an attractive platform for biopharmaceutical applications due to its 
minimal auto-fluorescence, nontoxicity, and non-specific binding. In this dissertation, a 
gold electro-less plating method was developed to introduce gold electrodes on the 
entrance and exit of AAO membranes. Gold electro-less plating on the pore entrance of 
AAO membranes brings three benefits. First, the surface of gold can be easily modified 
with different chemistry for the attachment of receptor chemistry and enzyme 
immobilization. Second, voltage can be applied on the micro-scale distance gold 
electrode on top and bottom of AAO membranes to generate high electric field and 
facilitate the ion transportation within the AAO membrane. Third, the pore size of AAO 
membrane can be easily controlled by changing the electro-less plating time onto the 
initial Au seed layer to a pore size match to protein or enzyme dimension. These three 
benefits of the nano-scale membrane electrodes are the basis for the three bio-
applications reported in this dissertation. 
An active membrane system based on nm-scale electrodes for continuous protein 
purification was first demonstrated in this dissertation.  The electrodes are located at the 
first 20nm of pore entrances to specifically capture targeted proteins and block non-
specific protein transport through the pores during the binding cycle.  During the release 
cycle, concentration of imidazole is controlled to keep the pore blocked while releasing 
proteins at the bottom edge of the electrode.  Numerical simulation of the pulse pumping 
cycles coupled with His-GFP releasing kinetic was used to determine and optimize pulse 
pumping condition, enabling mimic biological membranes for efficient protein separation. 
A separation factor for GFP:BSA of 9.7 was achieved with observed GFP electrophoretic 
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mobility of 3.1×10
-6
 cm
2
 s
-1
 V
-1
 at optimal pulse pumping conditions. Most importantly, 
the membrane electrode pulse pumping process show the ability to purify His6-OleD Loki 
variant directly from crude E. coli extracts expression broth, simplifying the separation 
process as well as reducing biopharmaceutical production costs.  
Nano-scale electrodes at the entrance and exit of AAO membranes for enzyme 
immobilized were demonstrated to mimic natural complex-enzyme system. Genetically 
modified His-tagged OleD Loki variant was immobilized onto nm-scale electrodes at the 
pore entrances/exits of modified AAO membranes through His6-tag affinity. Immobilized 
enzyme on membrane-electrodes system allows precise control of the substrates 
residence time through the enzyme, thus eliminating unwanted hydrolytic side reactions 
observed on solution-based enzymatic reaction. Two-step sequential reactions were 
demonstrated to mimic natural complex-enzyme system with the ability of discrete 
control of each independent step via selective reagent feedstock composition exposure of 
the top and/or bottom surface of immobilized membrane/electrode system. Finally, the 
system allows a convenient one-step immobilization and purification of N-His6-OleD 
Loki variant directly from crude E. coli extracts expression broth. This AAO 
membrane/electrode system offers an opportunity to expand the study and bio-catalytic 
utility of multi-enzyme cascades with directed mass transport 
A robust nanoporous membrane/gold electrodes system has demonstrated the 
continuous electroporation of HL-60 cells in a flowing white blood cell suspension 
culture. Gold electrodes were introduced on the entrance and exit of an AAO membrane 
through sputtering and gold electro-less plating. Voltages as low as 1V applied across the 
60 µm membrane thickness generated sufficient electric field, as simulated by COMSOL, 
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for cellular electroporation at pore entrances. PDMS micro-channels on the 
membrane/electrodes system with the 10 micron channel heights were created using 
standard soft-lithography designed to squeeze the leukocyte dimensions (~15 µm) into 
the high electric field electrode pore entrance. The low voltages, low joule heating and 
periodic poration sites allow for high cell viability (>90%) and 65% cell transfection 
efficiency. This device can be scaled up to increase the cell sample volume by simply 
varying the geometry of the micro-fluidic channel and/or pulse voltage frequency for 
enhanced residence time. Importantly, transfection reagent was electrophoretically 
pumped from a microscale reservoir across the membrane/electrode system to the micro-
fluidic channel, which reduced the amount reagent used by 8 fold compared to traditional 
electroporation strategies. In particular genetic modification of circulating white blood 
cells or diseased cells to express target protein/enzyme biomolecules is an important 
target platform enabled by this device system.   
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LIST OF ABBREVIATIONS 
 
4-Me-Umb                         4-methylumbelliferone 
AAO                                Aluminum oxide 
APTES                               Aminopropyltriethoxy silane 
BSA                                  Bovine serum albumin  
CNT                                 Carbon nanotube 
His-GFP                            His-tagged green fluorescence protein  
IMAC                               Immobilized metal ion affinity chromatography 
LY                                       Lucifer yellow 
NTA                                 Nα, Nα-Bis(carboxymethyl)-L-lysine 
PI                                        Propidium iodide 
PNP-Glc                            2-chloro-4-nitro-phenyl-β-D-glucopyranoside 
PDMS                                Polydimethylsiloxane  
PVC                                    Polyvinylchloride 
PTFE                                  Polytetrafluoroethylene 
PVDF                                 Polyvinylidene fluoride 
PE                                       Polyethylene 
PCTE                                 Polycarbonate track-etch 
SEM                                  Scanning Electron Microscope  
TIRF                                  Total internal reflection fluorescence 
UDP                                   Uridine Diphosphate 
IEC                                    Ionic exchange chromatography  
HIC                                    Hydrophobic interaction chromatography  
SEC                                    Size exclusion chromatography  
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